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Targeted prodrug delivery is one of the promising drug delivery systems for cancer treatment. 
Prodrug may improve the biological distribution and the half-life in the circulation as well as 
reduce the systemic toxicity and the kidney excretion of the drug. Prodrug is an important 
strategy to improve the solubility, permeability, stability and provide a means to circumvent the 
multi-drug resistance (MDR). MDR is caused by the overexpression of MDR transport proteins 
such as p-glycoproteins (p-gp) in the cell membrane, that efflux the drug by reducing the 
intracellular drug levels for cancer chemotherapy.  Tumors also acquire drug resistance through 
induction of MDR transport proteins.  At present, about 5-7% of the approved drugs worldwide 
can be classified as prodrugs and approximately 15% of all new drugs approved within 2001 and 
2002 were prodrugs. The conjugation of the drug with the polymer is a main strategy to form the 
polymeric prodrug of the synergistic or additive effect, which occurs with enhanced and 
simultaneous action of the drug and the polymer in destroying the cancer cells. The rationale for 
polymer conjugation is to mainly prolong the half-life of therapeutically active agents by 
increasing their hydrodynamic volume and hence decreasing their excretion rate. Polymer-
anticancer drug conjugate has been investigated and some prodrugs have been found successful. 
Polymers such as N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers, poly(ethylene 
glycol) and poly(L-glutamic acid) (PGA) have been used often as the carriers for anticancer drugs 
such as doxorubicin, paclitaxel, camphothecin and gemcitabine. Conjugation of TPGS should be 
an ideal solution for the drugs that have problems in adsorption, distribution, metabolism and 
excretion (ADME). 
  
Doxorubicin (DOX) is an effective anticancer agent for cancer treatment, which is hampered by 
its short plasma half life, low selectivity towards the tumor cells and serious side effects. This 
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research developed a prodrug strategy to conjugate DOX to d-α-tocopheryl polyethylene glycol 
succinate (TPGS) and folic acid (FOL) for targeted chemotherapy to enhance the therapeutic 
effects and reduce the side effects of the drug. We synthesized 2 conjugates, TPGS-DOX and 
TPGS-DOX-FOL to quantitatively evaluate the advantages of TPGS conjugation and FOL 
conjugation through passive and active targeting effects. The successful conjugation was 
confirmed by 1H NMR and FTIR. The DOX content in the conjugates was found to be 13wt% for 
TPGS-DOX and 6 wt% for TPGS-DOX-FOL.  The in vitro drug release from the conjugates were 
found pH dependent, which is in favor of cancer treatment. The in vitro cellular uptake and 
cytotoxicity were evaluated with MCF-7 breast cancer cells. It was found that the cellular uptake 
of DOX increased 15.2% by TPGS conjugation and further 6.3% by FOL conjugation after 0.5 
hour cell culture at 100 μM equivalent DOX concentration at 37°C, The mortality of the MCF-7 
cells showed 23.2% increase by TPGS conjugation and further 31.0% increase by targeting effect 
of FOL after 24 hour cell culture at 100 μM equivalent DOX concentration at 37°C.  These 
advantages were further confirmed by IC50 analysis. Cellular uptake of DOX, TPGS-DOX and 
TPGS-DOX-FOL conjugates were also visualized by confocal laser scanning microscopy 
(CLSM). The in vivo pharmacokinetics of the conjugates showed prolonged retention time of the 
DOX in plasma, where they have almost same half-life. The biodistribution data showed that the 
conjugates lowered the amount of drug accumulated in the heart, thereby reducing the 
cardiotoxicity, which is said to be the main side effect of the DOX. Also, the gastrointestinal side 
effect of the drug could be reduced by the TPGS-DOX-FOL conjugate, which has a 6.8- fold and 
5.3- fold lesser amount of drug in stomach and intestine respectively. 
 
The TPGS-DOX-FOL prodrug showed greater potential than the TPGS-DOX and DOX for it to 
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CHAPTER 1: INTRODUCTION 
 
1.1 General Background 
There has been intensive research on macromolecular ‘prodrugs’ in the field of drug delivery that 
refers to modification of the drug’s molecular structure such that it makes an inactive form to be 
administered and then to become active metabolite in the diseased cells. Prodrugs may improve 
the biological distribution and the half-life in the circulation as well as reduce the systemic 
toxicity and the kidney excretion of the drug (Cavallaro, Pitarresi et al. 2001; Zhang, Huey Lee et 
al. 2007). Prodrug is an important strategy to improve the solubility, permeability, stability and 
provide a means to circumvent the multidrug resistance (MDR). MDR is caused by the 
overexpression of MDR transport proteins such as p-glycoproteins (p-gp) in the cell membrane, 
that efflux the drug by reducing the intracellular drug levels for cancer chemotherapy (Schinkel 
1997; Stella and Nti-Addae 2007). Tumors also acquire drug resistance through induction of 
MDR transport proteins (Harris and Hochhauser 1992; Gottesman, Fojo et al. 2002). At present, 
about 5-7% of the approved drugs worldwide can be classified as prodrugs and approximately 
15% of all new drugs approved within 2001 and 2002 were prodrugs (Rautio, Kumpulainen et al. 
2008). The conjugation of the drug with the polymer is a main strategy to form the polymeric 
prodrug of the synergistic or additive effect, which occurs with enhanced and simultaneous action 
of the drug and the polymer in destroying the cancer cells (Tarek. M. Fahmy 2005). The rationale 
for polymer conjugation is to mainly prolong the half-life of therapeutically active agents by 
increasing their hydrodynamic volume and hence decreasing their excretion rate. Polymer-
anticancer drug conjugate has been investigated and some prodrugs have been found successful 
(Kopecek, Kopeckova et al. 2001; Jayant Khandare 2006; Pasut, Canal et al. 2008). Polymers 
such as N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers, poly(ethylene glycol) and 
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poly(L-glutamic acid) (PGA) have been used often as the carriers for anticancer drugs such as 
doxorubicin, paclitaxel, camphothecin and gemcitabine (Greenwald, Choe et al. 2003; Chytil, 
Etrych et al. 2006; Pasut, Canal et al. 2008). Several polymeric conjugates, for example, PEG 
conjugation of paclitaxel, camptothecin, methotrexate, PLA-paclitaxel, PEG-Doxorubicin, 
PLGA-paclitaxel have been developed earlier (Maeda, Seymour et al. 1992; Li, Yu et al. 1996; 
Riebeseel, Biedermann et al. 2002; Veronese, Schiavon et al. 2005; Pasut 2007).  
 
Most of the anticancer drugs do not differentiate between the cancerous cells and the healthy 
cells, leading to their systemic toxicity and side effects by affecting the normal cells (Brannon-
Peppas and Blanchette 2004). The aim of targeted drug delivery is to decrease the non-specificity 
to the healthy cells and increase the specificity to the cancer cells by attaching a targeting moiety 
to the inactive prodrug such that the active drug may then be released in the cancer cells without 
affecting the healthy cells (de Groot, Damen et al. 2001). The concept of targeting takes its effect 
when Paul Ehrlich (1854-1915) first postulated the ‘magic bullet’. Targeted drug delivery system 
has been considered as the promising way to increase the therapeutic effects of the antitumor 
drugs by being specific to tumor cells and by having prolonged duration of drug action 
(Sudimack and Lee 2000). This leads to reduction in the minimum effective dose of the drug. 
Though the “passive targeting” is quite effective by the enhanced permeation and retention (EPR) 
effect, “active targeting” by receptor mediated endocytosis (RME) is found to be more 
advantageous for most of the anticancer drugs (Tarek. M. Fahmy 2005). Several drug conjugates 
and drug encapsulated nanoparticles have been reported to actively target the cancer cells to 
increase the anticancer effects of the drug (Li, Yu et al. 1996; Veronese, Schiavon et al. 2005).  
 
Among the targeting moieties, vitamin folic acid (folate or FOL) has been widely employed as a 
targeting moiety for various anticancer drugs. It is attracted for its high binding affinity, ease of 
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modification, small size, stability during storage, and low cost (Lee and Low 1995; Reddy and 
Low 2000). The high-affinity folate receptor (FR), which is a cell surface-expressed molecule 
containing folate binding proteins called GPI (glycosyl phosphatidyl inositol) (Lu and Low 
2002), is overexpressed in almost all the carcinomas, but has a highly restricted distribution of 
expression in normal cells. For this reason, folic acid has been covalently conjugated to 
anticancer drugs for selective targeting against tumor, which can uptake the drug-FOL 
conjugation by the receptor mediated endocytosis (RME) (Lee and Low 1995). It was reported 
that folate-targeted liposomal doxorubicin in an MDR cell line can bypass the P-gp efflux effect 
as compared to the free doxorubicin, showing the effective targeting delivery of doxorubicin by 
folate (Goren, Horowitz et al. 2000). 
 
A water-soluble derivative of natural vitamin E, D-α-tocopheryl polyethylene glycol 1000 
succinate (TPGS) or vitamin E TPGS, which is an amphiphilic macromolecule comprising of 
hydrophilic polar head and a lipophilic alkyl tail, has been used as an effective emulsifier as well 
as a good solubilizer due to its bulky nature and larger surface area (Fisher 2002). Our group has 
successfully applied TPGS to prepare nanoparticles of biodegradable copolymers such as PLA-
TPGS and PLGA-TPGS for controlled and targeted delivery of paclitaxel, employed as a model 
anticancer drug (Mu and Feng 2003; Zhang and Feng 2006; Lee, Zhang et al. 2007). TPGS can 
enhance the solubility and bioavailability of poorly absorbed drugs by acting as a carrier in drug 
delivery systems, thus providing an effective way to improve the therapeutic efficiency and 
reduce the side effects of the anticancer drugs (Fisher 2002; Youk, Lee et al. 2005). It also 
increases the drug permeability across the cell membranes and enhances the absorption of the 
drug by inhibiting the P-glycoproteins, whereby acting as a vehicle for drug delivery system 
(Dintaman and Silverman 1999; Mu and Feng 2003). The increased emulsification efficiency and 
enhanced cellular uptake of nanoparticles by TPGS could result in increased cytotoxicity of the 
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drug to the cancer cells (Mu and Feng 2003). In recent studies, it is known that TPGS also 
possesses potent antitumor activity and has effective apoptosis inducing properties (Dintaman and 
Silverman 1999; Youk, Lee et al. 2005). TPGS should thus be an ideal candidate for polymeric 
conjugation of the drugs that have problems in pharmacokinetics, i.e. in the process of adsorption, 
distribution, metabolism and excretion (ADME).  
 
Doxorubicin (DOX), an anthracyclinic drug is a DNA-interacting drug for various cancers 
especially breast, ovarian, stomach, bladder, brain and lung cancers and is one of the most potent 
anticancer agents after its discovery in 1969 (Blum and Carter 1974). However, application of 
doxorubicin in clinical application has been limited because of its short half-life and its extremely 
high toxicity to the normal cells, especially the heart and gastrointestinal cells, as well (Blum and 
Carter 1974; Al-Shabanah, El-Kashef et al. 2000). It was indicated that when the cumulative dose 
of doxorubicin reaches 550 mg/m², the risks of developing cardiac side effects would 
dramatically increase (Petit 2004). Alternative formulations of doxorubicin have been developed 
recently, which include folate targeted doxorubicin, DOX-GA3 prodrug, HPMA-doxorubicin 
conjugate, doxorubicin-PEG-folate conjugate, DOX-PLGA-mPEG-folate micelles (Shiah, 
Dvorak et al. 2001; Yoo and Park 2004; Yoo and Park 2004; Lee, Na et al. 2005; Veronese, 
Schiavon et al. 2005). 
 
1.2 Objectives of this Research 
The objectives of this research is to develop a novel targeting polymeric prodrug, TPGS-DOX-
FOL, that is hoped to combine the advantages of TPGS and FOL applied individually in 
formulation of prodrugs. The polymer-drug conjugation was confirmed by ¹H NMR and FT-IR. 
The conjugation efficiency, stability and in vitro drug release from the conjugate were measured 
and analyzed. The cellular uptake and in vitro cytotoxicity of the TPGS-DOXFOL and TPGS-
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DOX conjugates were investigated by using MCF-7 breast cancer cells in close comparison with 
the pristine drug. Also, the pharmacokinetics and biodistribution were investigated in SD rats for 
pristine DOX, TPGS-DOX and TPGS-DOX-FOL conjugates. 
 
1.3 Thesis Organization 
The thesis includes six chapters. Chapter 1 gives a brief introduction to the research done. It 
comprises of general background of the project and its objectives as well. Chapter 2 gives a 
literature review, which was useful in developing novel ideas and concepts in this project and also 
gives supporting evidences. Chapter 3 gives the materials required and procedures adopted for the 
preparation of the conjugates. Chapter 4 explains the in vitro studies on drug release, cellular 
uptake and cell viability of the conjugates and the DOX. Chapter 5 gives the in vivo 
pharmacokinetics and biodistribution of the conjugates compared to the free DOX. Finally, the 
conclusions of the project are drawn based on the results and the interpretations done, followed 










CHAPTER 2: LITERATURE REVIEW 
 
2.1 Cancer: A Deadly Disease 
2.1.1 Overview of Cancer 
Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells 
that might affect almost any tissue of the body. The spreading of the cancerous cells is called 
‘metastasis’ (http://en.wikipedia.org/wiki/Metastasis). It can result in death, if the spread is not 
controlled. According to World Health Organization (WHO), cancer causes about 13 % of all the 
deaths (http://en.wikipedia.org/wiki/Cancer). Cancer is also called malignancy. A cancerous 
growth or tumor is referred to as a malignant growth or tumor. A non-malignant growth or tumor 
is referred to as benign. Benign tumors are not cancerous. There are dozens of cancer types such 
as prostate cancer, lung cancer, colorectal cancer, bladder cancer, cutaneous melanoma, 
pancreatic cancer, leukemia, breast cancer, endometrial cancer, ovarian cancer, brain cancer, non-
Hodgkin lymphoma etc. General classification of cancer includes Carcinoma, Sarcoma, 
Lymphoma, Leukemia, Germ cell tumor, Blastic tumor etc (http://en.wikipedia.org/wiki/Cancer).   
 
2.1.2 Cancer Prevalence, Causes and Risk Factors 
Cancer is one of the leading causes of death with around 10 million people being diagnosed with 
the disease each year. According to American Cancer Society, 7.6 million people died from 
cancer all over the world during 2007 and about 1.4 million new cancer cases are expected to be 
diagnosed in the year 2008 (http://en.wikipedia.org/wiki/Cancer). The 5-year relative survival 
rate for all cancers diagnosed between 1996 and 2003 is 66 %, up from 50 % 1975 – 1977. The 
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National Institutes of Health estimate overall costs of cancer in 2007 at $219.2 billion:$89.0 
billion for direct medical costs (total of all health expenditures); $18.2 billion for indirect 
morbidity costs (cost of lost productivity due to illness); $112.0 billion for indirect mortality costs 
(loss of productivity due to premature death) 
(http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf). By the year 2050, the 
global burden is expected to grow to 27 million new cancer cases and 17.5 million cancer deaths 
simply due to the growth and ageing of the population 
(http://www.cancer.org/downloads/STT/Global_Cancer_Facts_and_Figures_2007_rev.pdf).  
Cancer may affect people at all ages but in most cases the number of cancer patient increases with 
age. All cancers are almost caused by the abnormalities in the genetic material of the transformed 
cells. These genetic abnormalities in cancer affect 2 types of genes namely Tumor suppressor 
genes and Oncogenes. In cancer, the oncogenes are activated and the tumor suppressor genes are 
inactivated. Here, the oncogenes are responsible for the hyperactive growth and division of the 
cancer cells, to adjust in different environments and cause programmed cell death. Now the 
Tumor suppressor genes are responsible for the loss in control over the cell cycle, adhesion with 
other tissues and interaction with the immune cells. The 2 wide factors that cause the cancerous 
cells are the external factors and the internal factors. The external factors include  
 Tobacco smoking 
 Chemicals 
 Radiation  
 Infections 
 Alcohol  
 Poor diet  
 Lack of physical activity or overweight  
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The internal factors include  
 Inherited mutations  
 Hormones 
 Growing older  
 Immune conditions.  
These factors are said to be the most common risk factors for cancer. Many of these risk factors 
can be avoided and several of these factors may act together to cause normal cells to become 
cancerous. The chemicals that cause cancer are called carcinogens and those chemicals that cause 
cancer through mutations in DNA are called mutagens. All mutagens are carcinogens, but all 
carcinogens are not mutagens. They cause rapid rates of mitosis of the cells and thus inactivate 
the enzyme that does the DNA repair. One of the most important carcinogens is tobacco. 
Smoking and its related disease remains the world’s most preventable cause of death and so is the 
cancer also. According to National Cancer Institute (NCI), each year, more than 180,000 
Americans die from cancer that is related to tobacco use. Tobacco smoking accounts for at least 
30 % of all cancer deaths and 87 % of lung cancer deaths. The risk of developing lung cancer is 
about 23 times higher in male smokers and 13 times higher in female smokers compared to non-
smokers (http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf). Also, quitting 
smoking substantially decreases the risk of cancer. Prolonged exposure of radiation such as ultra 
violet radiation from the sun, sun lamps and tanning booths causes early ageing of the skin and 
skin damage that can lead to skin cancer. Ionizing radiation usually causes cell damage that leads 
to cancer. This kind of radiation comes from the rays that enter the earth’s atmosphere from outer 
space, radioactive fallout, radon gas, x-rays and other sources. The radioactive fallout can come 
from accidents at nuclear power plants or from the production, testing or use of atomic weapons. 
People exposed to fallout may have an increased risk of cancer, especially leukemia and cancer of 
thyroid, breast, lung and stomach. Radon is a radioactive gas that we cannot see, smell or taste. 
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People who work in mines may be exposed to radon. People exposed to radon are at increased 
risk of lung cancer. The risk of cancer from low dose x-rays is very small and that from the 
radiation therapy is slightly higher. Being infected with certain viruses or bacteria may increase 
the risk of developing cancer. HPV (Human papillomavirus) infection is the main cause of 
cervical cancer. It also may be a risk factor for other types of cancer. Hepatitis B and Hepatitis C 
viruses can cause liver cancer after many years of infection. Infection with HTLV-1 (Human T-
cell leukemia/lymphoma virus) increases a person’s risk of developing lymphoma and leukemia. 
HIV (Human Immunodeficiency Virus) is the virus that causes AIDS. People who possess HIV 
have a greater risk of having cancer such as lymphoma and a rare cancer called ‘Kaposi’s 
sarcoma’. EBV (Epstein-Barr Virus) infection can cause lymphoma. Human herpesvirus 8 
(HHV8) is a risk factor for kaposi’s sarcoma. Helicobacter pylori bacteria can cause stomach 
ulcers. It can also cause stomach cancer and lymphoma in stomach lining. The viruses are 
responsible for about 15% of the cancers worldwide.  
The hormonal imbalance causes cancer due to the hormones acting in the same manner as the 
non-mutagenic carcinogens. Hormones may increase the risk of breast cancer, heart attack, stroke 
or blood clot. Diethylsilbestrol (DES), a form of estrogen, was given to pregnant woman in the 
United States between about 1940 and 1971. Woman who took DES during their pregnancy may 
have a slightly higher risk of developing breast cancer. Their daughters have an increased risk of 
developing a rare type of cancer of cervix. The effects on their sons are under study. The immune 
system malfunction also causes cancer to a greater extent and heredity causes cancer as well. 
Most cancers develop because of changes (mutations) in genes. A normal cell may become a 
cancer cell after a series of gene changes occur. Tobacco use, certain viruses, or other factors in a 
person's lifestyle or environment can cause such changes in certain types of cells. Some gene 
changes that increase the risk of cancer are passed from parent to child. These changes are present 
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at birth in all cells of the body. It is uncommon for cancer to run in a family. However, certain 
types of cancer do occur more often in some families than in the rest of the population. For 
example, melanoma and cancers of the breast, ovary, prostate, and colon sometimes run in 
families. Several cases of the same cancer type in a family may be linked to inherited gene 
changes, which may increase the chance of developing cancers. However, environmental factors 
may also be involved. Most of the time, multiple cases of cancer in a family are just a matter of 
chance. Having more than two drinks each day for many years may increase the chance of 
developing cancers of the mouth, throat, esophagus, larynx, liver, and breast. The risk increases 
with the amount of alcohol that a person drinks. For most of these cancers, the risk is higher for a 
drinker who uses tobacco. People who have a poor diet, do not have enough physical activity, or 
are overweight may be at increased risk of several types of cancer. For example, studies suggest 
that people whose diet is high in fat have an increased risk of cancers of the colon, uterus, and 
prostate. Lack of physical activity and being overweight are risk factors for cancers of the breast, 
colon, esophagus, kidney, and uterus.   
 
2.1.3 Cancer Treatment 
The treatment for cancer varies based on the type of cancer and its stage. The stage of a cancer 
refers to how much it has grown and whether the tumor has spread from its original location. The 
goal of the treatment is the complete removal of the cancer without damage to the rest of the 
body. Cancer can be treated by many methods such as  
 Surgery 




 Immunotherapy  
 Targeted therapy  
 Hormonal therapy etc. 
Surgery is done by removing the cancer in the respective location by physical operation. It is 
usually used to remove small cancers and those that are not metastasized. The goal of the surgery 
can be the removal of either the tumor alone or the entire organ. When the cancer has 
metastasized to other sites in the body prior to surgery, complete surgical excision is usually 
impossible. Surgery is also used to control the symptoms like spinal cord compression or bowel 
obstruction. Radiation therapy is the use of ionizing radiation to kill cancer cells and shrink 
tumors. It can be administered externally or internally. The effects of radiation therapy are 
localized and confined to the region being treated. Radiation therapy injures or destroys cells in 
the area being treated by damaging their genetic material, making it impossible for these cells to 
continue to grow and divide. Although radiation damages both cancer cells and normal cells, 
most normal cells can recover from the effects of radiation and function properly. The goal of 
radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby 
healthy tissue. Radiation therapy may be used to treat almost every type of solid tumor, including 
cancers of the brain, breast, cervix, larynx, lung, pancreas, prostate, skin, stomach, uterus, or soft 
tissue sarcomas. Radiation is also used to treat leukemia and lymphoma. Chemotherapy is the 
treatment of cancer with drugs called anticancer drugs, that can destroy cancer cells. In current 
usage, the term "chemotherapy" usually refers to cytotoxic drugs which affect rapidly dividing 
cells. Chemotherapy drugs interfere with cell division in various possible ways, e.g. with the 
duplication of DNA or the separation of newly formed chromosomes. Most forms of 
chemotherapy target all rapidly dividing cells and are not specific for cancer cells, although some 
degree of specificity may come from the inability of many cancer cells to repair DNA damage, 
while normal cells generally can. Hence, chemotherapy has the potential to harm healthy tissue, 
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especially those tissues like intestinal lining that have a high replacement rate. These cells usually 
repair themselves after chemotherapy. Because some drugs work better together than alone, two 
or more drugs are often given at the same time and this is called "combination chemotherapy". 
Most chemotherapy regimens are given in a combination. Targeted therapy constitutes the use of 
agents specific for the deregulated proteins of cancer cells. Small molecule targeted therapy drugs 
like tyrosine kinase inhibitors, are generally inhibitors of enzymatic domains on mutated, 
overexpressed, or otherwise critical proteins within the cancer cell. Monoclonal antibody therapy 
is another strategy in which the therapeutic agent is an antibody which specifically binds to a 
protein on the surface of the cancer cells. The anti-HER2/neu antibody trastuzumab (Herceptin) 
used in breast cancer, and the anti-CD20 antibody rituximab, used in a variety of B-cell 
malignancies are some of the antibodies used in targeting and treating cancer cells. Cancer 
immunotherapy induces the person’s own immune system to destroy the tumor. Contemporary 
methods for generating an immune response against tumours include intravesical BCG 
immunotherapy for superficial bladder cancer, and use of interferons and other cytokines to 
induce an immune response in renal cell carcinoma and melanoma patients. Vaccines that are 
used to generate specific immune responses are the subject of intensive research for various 
tumors. The growth of some cancers can be inhibited by providing or blocking certain hormones. 
Common examples of hormone-sensitive tumors include certain types of breast and prostate 
cancers. Removing or blocking estrogen or testosterone is often an important additional 
treatment. In certain cancers, administration of hormone agonists, such as progestogens may be 
therapeutically beneficial. Angiogenesis inhibitors prevent the extensive growth of blood vessels 
(angiogenesis) that tumors require to survive and thus it can be considered as a treatment for 
cancer. Some inhibitors, such as bevacizumab, have been approved and are in clinical use. One of 
the main problems with anti-angiogenesis drugs is that many factors stimulate blood vessel 
growth, in normal cells and cancer. Anti-angiogenesis drugs only target one factor, so the other 
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factors continue to stimulate blood vessel growth. Other problems include route of administration, 
maintenance of stability and activity and targeting at the tumor vasculature. 
 
2.1.4 Cancer Chemotherapy and its Evolution 
Chemotherapy refers to “treatment with drugs or chemicals” to destroy the cancer cells. The 
drugs destroy the cells by interfering with their life cycle. Cancer cells are more sensitive to 
chemotherapy than healthy cells because they divide more frequently. Healthy cells can also be 
affected by chemotherapy, especially the rapidly dividing cells of the skin, the lining of the 
stomach, the intestines and the bladder. Chemotherapy is often the first choice for treating many 
cancers. It differs from surgery or radiation in that it is almost always used as a systemic 
treatment. This means the medicines travel throughout the body to reach cancer cells wherever 
they may have spread. Treatments like radiation and surgery act in a specific area such as the 
breast, lung, or colon, and so are considered local treatments. More than 100 drugs are used today 
for chemotherapy, either alone or in combination with other drugs or treatments. As research 
continues, more drugs are expected to become available. Chemotherapy drugs can be divided into 
several groups based on factors such as how they work, their chemical structure, and their 
relationship to another drug. Some chemotherapy drugs are grouped together because they were 
derived from the same plant. Because some drugs act in more than one way, they may belong to 
more than one group. Nanotechnology has been developed in recent times to design more 
comfortable and effective drug formulations that are patient friendly. The common types of 
chemotherapeutic drugs are the following.  
 Alkylating agents – They directly damage DNA to prevent the cancer cell from reproducing. 
Alkylating agents are used to treat many different cancers, including acute and chronic 
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leukemia, lymphoma, Hodgkin disease, multiple myeloma, sarcoma, as well as cancers of the 
lung, breast, and ovary. Because these drugs damage DNA, they can cause long-term damage 
to the bone marrow. In a few rare cases, this can eventually lead to acute leukemia. The risk 
of leukemia from alkylating agents is "dose-dependent," meaning that the risk is small with 
lower doses, but goes up as the total amount of drug used gets higher. The risk of leukemia 
after alkylating agents is highest 5-10 years after treatment. The different alkylating agents 
include nitrogen mustards such as mechlorethamine (nitrogen mustard), chlorambucil, 
cyclophosphamide (Cytoxan®), ifosfamide, and melphalan, nitrosoureas which include 
streptozocin, carmustine (BCNU), and lomustine, alkyl sulfonates that include busulfan, 
triazines such as dacarbazine (DTIC), and temozolomide (Temodar®), ethylenimines such as 
thiotepa and altretamine (hexamethylmelamine). The platinum drugs (cisplatin, carboplatin, 
and oxalaplatin) are sometimes grouped with alkylating agents because they kill cells in a 
similar way. These drugs are less likely than the alkylating agents to cause leukemia.    
 Antimetabolites - Antimetabolites are a class of drugs that interfere with DNA and RNA 
growth by substituting for the normal building blocks of RNA and DNA. These agents 
damage cells during the S phase. They are commonly used to treat leukemias, tumors of the 
breast, ovary, and the intestinal tract, as well as other cancers. Examples of antimetabolites 
include 5-fluorouracil (5-FU), capecitabine (Xeloda®), 6-mercaptopurine (6-MP), 
methotrexate, gemcitabine (Gemzar®), cytarabine (Ara-C®), fludarabine, and pemetrexed 
(Alimta®).  
 Anthracyclines - Anthracyclines are anti-tumor antibiotics that interfere with enzymes 
involved in DNA replication. These agents work in all phases of the cell cycle. Thus, they are 
widely used for a variety of cancers. A major consideration when giving these drugs is that 
they can permanently damage the heart if given in high doses. For this reason, lifetime dose 
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limits are often placed on these drugs. Examples of anthracyclines include daunorubicin, 
doxorubicin (Adriamycin®), epirubicin, and idarubicin.  
 Other anti-tumor antibiotics – They include the drugs actinomycin-D, bleomycin, and 
mitomycin-C. Mitoxantrone is an anti-tumor antibiotic that is similar to doxorubicin in many 
ways, including the potential for damaging the heart. This drug also acts as a topoisomerase II 
inhibitor (see below), and can lead to treatment-related leukemia. Mitoxantrone is used to 
treat prostate cancer, breast cancer, lymphoma, and leukemia.  
 Topoisomerase inhibitors - These drugs interfere with enzymes called topoisomerases, which 
help separate the strands of DNA so they can be copied. They are used to treat certain 
leukemias, as well as lung, ovarian, gastrointestinal, and other cancers. Examples of 
topoisomerase I inhibitors include topotecan and irinotecan (CPT-11). Examples of 
topoisomerase II inhibitors include etoposide (VP-16) and teniposide. Mitoxantrone also 
inhibits topoisomerase II. 
 Mitotic inhibitors - Mitotic inhibitors are often plant alkaloids and other compounds derived 
from natural products. They can stop mitosis or inhibit enzymes from making proteins needed 
for cell reproduction. These work during the M phase of the cell cycle but can damage cells 
in all phases. They are used to treat many different types of cancer including breast, lung, 
myelomas, lymphomas, and leukemias. These drugs are known for their potential to cause 
peripheral nerve damage, which can be a dose-limiting side effect. Examples of mitotic 
inhibitors include the taxanes like paclitaxel (Taxol®), docetaxel (Taxotere®), epothilones like 
ixabepilone  (Ixempra®), the vinca alkaloids such as vinblastine (Velban®), vincristine 
(Oncovin®), and vinorelbine (Navelbine®) and estramustine like (Emcyt®). 
 Corticosteroids - Steroids are natural hormones and hormone-like drugs that are useful in 
treating some types of cancer (lymphoma, leukemias, and multiple myeloma) as well as other 
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illnesses. When these drugs are used to kill cancer cells or slow their growth, they are 
considered chemotherapy drugs. Corticosteroids are also commonly used as anti-emetics to 
help prevent nausea and vomiting caused by chemotherapy. Examples include prednisone, 








Fig 2-1 Timeline of events in the development of cancer chemotherapy (DeVita and Chu 2008) 
(continued) 
 
2.1.5 Barriers encountered in Cancer Chemotherapy 
There are four main barriers encountered in cancer chemotherapy which gives rise to increased 
side effects. They are as follows: 
2.1.5.1 Solubility 
Solubility has been identified as a critical parameter in cancer chemotherapy. The drug 
administered either intravenously or orally has to be soluble in the blood or should have a better 
oral absorption respectively. Since most of the anticancer drugs are hydrophobic, they have a very 
low solubility, which results in poor therapeutic effect. Research has been carried out to find a 
method that increases the solubility of these drugs. One such method is the use of polymers to 
form prodrugs. Prodrugs are polymer-drug conjugates that remain inactive till it reaches the site 
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of action (Stella and Nti-Addae 2007). Also, they found that polymeric nanoparticles can increase 
the oral absorption of the drugs in the intestine as well as increase the solubility of drugs in the 
blood.  
 
2.1.5.2 Macrophages Uptake 
Macrophages are white blood cells within tissues, produced by the division of monocytes. Human 
macrophages are about 21 micrometres in diameter. The important role of macrophages is to find 
the foreign materials that enter the blood, engulf them and digest them. It is a protective system to 
prevent the body from attach of pathogens that enter the blood. This is considered to be a barrier 
for chemotherapy, because the anticancer drugs can be recognized as foreign particles and can be 
digested by the macrophages, which results in very poor treatment.  
   
Fig 2-2 Macrophages uptake by phagocytosis 
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When a macrophage ingests a pathogen, the pathogen becomes trapped in a phagosome, which 
then fuses with a lysosome. Within the phagolysosome, enzymes and toxic peroxides digest the 
pathogen. However, some bacteria, such as Mycobacterium tuberculosis, have become resistant 
to these methods of digestion. Macrophages can digest more than 100 bacteria before they finally 
die due to their own digestive compounds.  
 
2.1.5.3 Multi Drug Resistance (MDR effect) 
The MDR is defined as the resistance of tumor cells to the cytostatic or cytotoxic actions of 
multiple, structurally dissimilar and functionally divergent drugs commonly used in cancer 
chemotherapy (Gottesman 1993). The most studied mechanism of MDR is that resulting from the 
overexpression of ABC transporters, localized in the cell membrane, which cause this 
phenomenon by extruding a variety of chemotherapeutic agents from tumor cells. The ABC 
transporters are primary-active transporters, driven by energy released from ATP by inherent 
ATPase activity, and exporting substrates from the cell against a chemical gradient. Three major 
ABC transporters are involved in MDR, (1) P-glycoproteins (P-gp), (2) ABCG2 protein and the 
(3) multidrug resistance associated proteins (Perez-Tomas 2006). P-glycoproteins are the most 
important transporters resulting in decreased anticancer activity of the drugs. 
P-glycoproteins were discovered by their ability to confer multidrug resistance (MDR) to cancer 
cells (Juliano and Ling 1976; Gottesman, Hrycyna et al. 1995). P-gps are large, glycosylated 
membrane proteins which localize predominantly to the plasma membrane of the cell. They 






Fig 2-3 Human P-glycoprotein (Perez-Tomas 2006) 
 
The most striking property of the drug transporting P-gps is their ability to transport an incredibly 
diverse range of compounds, which do not share obvious structural characteristics. Interestingly, 
many of these compounds are of natural origin (derived from plants, bacteria, fungi, sponges), or 
minor variants of natural products. The only common structural denominator identified so far is 
that all transported P-gp substrates are amphipathic in nature. This probably relates to the 
mechanism of drug translocation by P-gp, which may be dependent on the ability of the drug to 
insert in one hemileaflet of the membrane lipid bilayer (Higgins and Gottesman 1992) as is also 
discussed elsewhere in this volume. As a consequence of the promiscuity of the P-gps, they can 
transport a large number of medically relevant compounds. These include a range of widely used 
anticancer drugs, such as anthracyclines, Vinca alkaloids, epipodophyllotoxins,and taxanes, but 
many other drugs and pesticides too, such as the immunosuppressive agents cyclosporin A and 
FK506 (Saeki, Ueda et al. 1993), cardiac glycosides such as digoxin (Tanigawara, Okamura et al. 
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1992), antibiotics like rifampicin and the anthelmintic pesticide ivermectin (Schinkel, Smit et al. 
1994; Schinkel, Wagenaar et al. 1995). The properties of P-gp includes the protection against 
natural toxins, hormone transport and reproduction, functional role in hematological 
compartment, role in cell volume regulation, role in lipid transport and other functions. The P-gp 
plays an important role in the blood-brain barrier (Bradbury 1985; Schinkel 1997). They are also 
said to limit oral absorption and brain entry through HIV-1 protease inhibitors (Kim, Fromm et al. 
1998). 
  
Fig 2-4 Mechanism of P-glycoproteins 
 
2.1.5.4 Stability and Absorption in Small Intestine 
The stability and the absorption in small intestine is one of the barriers in delivering the drug to 
the cancer cells. This is in the case of oral chemotherapy, where absorption in small intestine and 
crossing the intestinal membrane by diffusion plays an important role. The inner walls of the 
small intestine have thousands of finger-like outgrowths called villi. The villi increase the surface 
area for absorption of the digested food. Each villus has a network of thin and small blood vessels 
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close to its surface. The surface of the villi absorbs the digested food materials. The absorbed 
substances are transported via the blood vessels to different organs of the body where they are 
used to build complex substances such as the proteins required by our body. This is called 
assimilation. If an orally administered drug can harm the stomach lining or decomposes in the 
acidic environment of the stomach, a tablet or capsule of the drug can be coated with a substance 
intended to prevent it from dissolving until it reaches the small intestine. These protective 
coatings are described as enteric, which refers to the small intestine. For the coatings to dissolve, 
they must come in contact with the less acidic environment of the small intestine or with the 
digestive enzymes there. 
 
2.1.6 Problems  and Side Effects in Chemotherapy 
Chemotherapy is a very complicated procedure that gives rise to a high or low risk making it an 
ineffective or effective therapy respectively. The risk is due to the high toxicity of the 
chemotherapeutic drug that finally leads to side effects. The side effects of chemotherapy are 
usually caused by its effects on healthy cells. Chemotherapy interferes with cell duplication. 
Since cancer cells divide rapidly they are the targets of the treatment. Some of the most common 
side effects of chemotherapy are listed below. 
(1) Blood-Related side effects – One of the most important side effects of chemotherapy is its 
effect on blood cells namely RBCs (Red Blood Cells), WBCs (White Blood Cells) and 
Platelets. Normally blood cells are the most rapidly dividing cells in the body, and therefore, 
the most sensitive to chemotherapy. Chemotherapeutic agents may usually decrease 
temporarily the levels of these blood components. The time when the blood components are 
at the lowest level is called as the “nadir”, and usually occurs one to two weeks after the 
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chemotherapy had begun. When the RBCs decrease significantly, a condition known as 
“anemia” occurs. When the WBCs decrease significantly, a condition known as 
“neutropenia” occurs. When the platelets decrease significantly, a condition known as 
“thrombocytopenia” occurs. Internal bleeding causes anemia. These side effects can be 
treated with blood transfusions and new medications that speed up the replacement of the lost 
blood cells.  
(2) Hair loss – This is another side effect of chemotherapy and is also called “alopecia”. Cells in 
the hair follicles are responsible for hair growth and maintenance. Because these cells divide 
rapidly, they are affected by chemotherapeutic drugs. Hair loss may affect the scalp, face and 
the rest of the body. The rate of hair loss may be rapid. Hair loss is usually temporary.  
(3) Nausea and vomiting – Some chemotherapeutic agents can lead to nausea and vomiting. 
Strong anti-nausea and anti-vomiting medications are available for this purpose. Drinking 
clear liquids before chemotherapy helps to decrease nausea and vomiting.  
(4) Sore throat – The cells lining the inside of the mouth and throat divide rapidly. They are also 
continuously exposed to infections from the food. Chemotherapy can cause inflammation and 
infections inside the mouth. This condition is known as “stomatitis” makes swallowing 
difficult and painful.  
(5) Diarrhea – Because the cells lining the intestines and colon divide constantly, they can be 
affected by chemotherapy. This can cause diarrhea. Increasing fluid intake usually keeps the 
patient hydrated.  
(6) Constipation – It is sometimes caused by chemotherapy. Maintaining a high fiber diet helps 
to decrease the side effect.  
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(7) Effect on the skin – because the cells lining the skin divide fairly and rapidly, they are 
susceptible to chemotherapy. This can cause skin dryness and increased reaction to the 
sunlight.  
(8) Fertility and sexuality – Men wishing to father children may consider sperm banking prior to 
the start of chemotherapy. Chemotherapy may affect sperm count and viability. Some woman 
may have changes in their menstrual cycle because of chemotherapy, which could result in 
total absence of periods. Chemotherapy could also cause dryness of the vagina.  
(9) Other possible side effects – Besides the common side effects of the chemotherapy, other side 
effects can happen, depending on the type of cancer, the type of chemotherapy treatment and 
the patient’s medical condition.    
These side effects are due to certain factors such as dosage form of the drug, pharmacokinetics of 
the drug, toxicity associated with the drug and the drug resistance by the cancer cells. The drug 
resistance is of three categories namely pharmacokinetic resistance (due to low concentration of 
drug), kinetic resistance (small fraction of cells in susceptible state) and genetic resistance (due to 
biochemical resistance). A very important resistance developed by the cancer cells is the Multi 
Drug Resistance (MDR). This resistance is caused by the membrane proteins, P-glycoproteins 
that causes the efflux of the drug from the cell and results in low drug accumulation in the cancer 
cells. It usually acts as the efflux pump to protect the cancer cells (Krishna and Mayer 2000). The 
dosage form of the anti cancer drug is also a factor for the side effects. Mostly the anti cancer 
drugs are hydrophobic in nature and that it has to be made hydrophilic in order for it to be soluble 
in blood and available for the cancer cells. For this purpose, adjuvants are added to the drugs, 
which cause the side effects. In the case of anti cancer drug Paclitaxel, Cremophor EL has been 
added as an adjuvant in order to improve its availability to cancer cells and to improve its 
solubility and this was found to have serious side effects like hypersensitivity, nephrotoxicity, 
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cardiotoxicity etc. The longer time exposure is believed to have better anti cancer effects and thus 
sufficient drug concentration for longer time is required to kill cancer cells in a better way. Anti 
cancer drugs affect healthy cells also. So this might cause toxicity to the normal cells along with 
the cancerous cells that might cause side effects affecting the liver, heart, kidney etc (Feng SS 
2003).  
 
2.1.7 Engineering Aspects of Cancer Chemotherapy 
The main engineering aspects of the cancer chemotherapy is to achieve the best efficiency of the 
anticancer drugs with the least side effects. The chemotherapy involves toxic drugs which are 
used to treat cancer cells. The problem comes from the anticancer drugs like doxorubicin, 
paclitaxel, fluorouracil etc itself. The efficiency and the side effects are not interrelated. 
Sometimes the drug that has maximum efficacy may have higher side effects and vice versa. The 
side effects of the anticancer drugs not only decrease effective chemotherapy, but also reduce the 
life of patients. Chemotherapeutic engineering represents a new challenge for chemical engineers. 
Chemical engineering made important contributions in providing new products and services to 
meet the needs of modern civilization and improve the quality of life in the past century. 
 
2.2 Polymers as Drug Carriers in Drug Delivery System 
Different drug delivery systems have been developed in the last few years to improve 
pharmacokinetic and pharmacodynamic profile of the drugs (Reddy 2000) . Many polymers have 




Fig 2-5 Emergence of anticancer polymer therapeutics (Duncan 2006) 
 
 In general, an ideal polymer for drug delivery should have characteristics like (1) 
biodegradability or adequate molecular weight that allows elimination from the body to avoid 
progressive accumulation in vivo, (2) low polydispersity, to ensure an acceptable homogeneity of 
the final drug formulations and (3) longer residence time either to prolong the drug action or to 
allow distribution and accumulation in respective body compartments. The polymers used for 
drug delivery are given as follows: 
 
2.2.1 Synthetic Polymers 
It includes PEG, N-(2-hydroxypropyl)-methacrylamide copolymers (HPMA), 
poly(ethyleneimine) (PEI), poly(acroloylmorpholine) (PAcM), poly(vinylpyrrolidone) (PVP), 
polyamidoamines, divinylethermaleic anhydride/acid copolymer (DIVEMA), poly(styrene-co-
maleic acid/anhydride) (SMA), polyvinylalcohol (PVA).  
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Vinyl polymers are synthesized by radical polymerization of the respective vinyl monomer or by 
copolymerization of 2 or more different monomers. They can bring about high drug loading due 
to the reactive pendant groups and thus acts as a polymeric carrier. They are usually non 
biodegradable and therefore their molecular weight must fall below the renal threshold filtration 
for these molecules i.e. 40-50 kDa.  
HPMA is one of most widely studied polymers (Kopecek J. 1973; Duncan R. 1983; Lloyd JB 
1983). Its derivative with the antitumor drug doxorubicin was the first drug-conjugate design 
developed. This was developed based on the Ringsdorf model and it entered the clinical trials (Duncan 
2001). Doxorubicin was linked via peptidyl spacer to polymer, where the linker is designed to be stable 
during plasma circulation, but promptly cleaved by lysosomal cathepsin B after cellular endocytosis 
(Duncan R 1983). HPMA copolymer was studied also in campothecin (Schoemaker, van Kesteren et al. 
2002), paclitaxel (Meerum Terwogt, ten Bokkel Huinink et al. 2001) and Pt-malonate conjugation (Gianasi, 
Buckley et al. 2002; Rademaker-Lakhai, Terret et al. 2004), drugs that suffer from low solubility in water, 
which can be solved by polymer conjugation. 
SMA is a hydrophobic copolymer which is obtained from maleic anhydride and styrene. Neocarcinostatin 
(NCS)-SMA is a most known conjugate, which exhibits cytotoxicity against mammalian cells. The 
conjugation was allowed for a half-life increase of 10-20 times with respect to native protein and by the 
EPR effect, the accumulation in tumor tissue was 30-fold that in muscle (Maeda 1991). 
    




PEG is synthesized by the ring opening polymerization of ethylene oxide using methanol or water 
as initiator to yield methoxy-PEG or diol PEG, respectively. It has unique properties such as (1) 
lack of immunogenicity, antigenicity and toxicity, (2) high solubility in water and in many 
organic solvents, (3) high hydration and flexibility of the chain, (4) low polydispersity, (5) 
prolonged pharmacokinetic properties of drugs and (6) approval by FDA for human use (Pasut 
2007). PEG is considered a non-biodegradable polymer. But slow degradation by alcohol 
dehydrogenase (Kawai 2002), aldehyde dehydrogenase (Mehvar 2000) and cytochrome P-450  
(Beranova, Wasserbauer et al. 1990) has been reported for PEG oligomer. Therefore, its body 
clearance depends upon its molecular weight. The main limitation of PEG as drug carrier is the 
presence of only two reactive groups which leads to an intrinsically low drug payload. To 
overcome this limitation, the construction of Dendron structure at the PEG’s end chain has been 
afforded, leading to enhanced drug loading (Choe, Conover et al. 2002; Schiavon, Pasut et al. 
2004). Some of the conjugates prepared with PEG are PEG-camptothecin, PEG-Doxorubicin etc. 
 
    
                                     Scheme 2-2 Chemical structure of PEG 
 
2.2.2 Natural Polymers  
It includes dextran, pullulan, mannan, dextrin, chitosans, hyaluronic acid, proteins. 
Polysaccharides have been widely studied in drug delivery. Their pharmacokinetic is largely 
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influenced by molecular weight, electric charge, chemical modifications, and degree of 
polydispersity and/or branching. Their applications range from delivery of small drugs to 
preparation of protein conjugates (Mehvar 2003). Dextran is the most widely used polymer of this 
class (Brocchini S 1999). Dextran-Doxorubicin conjugate entered the phase I clinical trials, but 
displayed a toxicity attributed to uptake of dextran by the liver reticuloendothelial cells 
(Danhauser-Riedl, Hausmann et al. 1993). 
 
2.2.3 Pseudosynthetic Polymers  
It includes PGA, poly(L-lysine), poly(malic acid), poly(aspartamides), poly((N-hydroxyethyl)-L-
glutamine) (PHEG). PGA, poly(L-lysine), poly(aspartamides), PHEG are easily synthesized and 
are biodegradable. The drug loading is high because any monomer possess a side reactive group 
for coupling. In this, PGA-Paclitaxel conjugate has reached the most advanced clinical stage. 
Here PGA with a 17,000 Da molecular weight was conjugated to Paclitaxel through an ester bond 
reaching the better high loading of 37% (Singer, Baker et al. 2003). The final conjugate had a 
molecular weight of 49,000 Da. 
 
2.3 Drug Targeting to Cancer Cells 
Targeted drug delivery to cancer cells is generally categorized as either passive or active targeting 
in the case of the presence or absence of site-directing ligands, respectively (Allen TM 1996; 
Willis and Forssen 1998). Targeted drug delivery systems promise to expand the therapeutic 
effects of drugs by increasing delivery to the target tissue as well as the target – non-target tissue 
ratio, which leads to a reduction in minimum effective dose and toxicity of the drug, and an 
improvement in therapeutic efficacy at equivalent plasma concentrations. 
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2.3.1 Active Targeting 
Active targeting requires site-directed ligands to bind and interact with surfaces at the target site. 
Various targeting moieties or ligands against tumor-cell-specific receptors have been immobilized 
on the surface of drug carriers to deliver them within cells via receptor mediated endocytosis. 
Targeting ligands attached to the surface of nanoparticles may act as ‘homing devices’, improving 
the selective delivery of drug to specific tissue and cells. This is especially true for targets that are 
readily accessible from the vasculature.  
 
 
Fig 2-6 List of ligand targeted nanoparticulate systems evaluated for in vitro and in vivo 
therapeutics delivery (Tarek. M. Fahmy 2005) 
 
When tumor cells were administered intravenously in mice, active targeting was found to increase 
the therapeutic index of the drug when tumors were just growing (Ahmad, Longenecker et al. 
1993; Moase, Qi et al. 2001). 
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2.3.1.1 Concept of “Magic Bullets”  
                                        
         Fig 2-7 Dr. Paul Ehrlich (Father of Chemotherapy) 
 
The concept of targeted therapy was first postulated by Paul Ehrlich by introducing ‘magic bullet’ 
in the year 1906.  
 
        Fig 2-8 Cancer Therapy Progress since Ehrlich’s finding (Strebhardt and Ullrich 2008) 
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Since then, magic bullet started finding the usage in clinical trials based on (1) finding the proper 
target for a particular disease state, (2) finding a drug that effectively treats the disease and (3) 
finding a means of carrying the drug in a stable form to specific sites while avoiding non specific 
interactions that clears any foreign particles from the body. 
 
2.3.1.2 Folic Acid 
Folic Acid is one of the most extensively studied small molecule targeting moieties for drug 
delivery, which is used to avoid non-specific attacks of the anticancer drug on normal tissues as 
well as to increase their cellular uptake within the target cells as studied in several previous 
studies (Lu JY 1999; Reddy and Low 2000; Lu and Low 2002). Folate targeted drug delivery has 
emerged as an alternative therapy for the treatment and imaging of many cancers and 
inflammatory diseases. It was said that the administration of folic acid accelerated the progression 
of leukemia (Farber, Cutler et al. 1947; Kim 2008). Folates are low molecular weight pterin-
based vitamins required by eukaryotic cells for one-carbon metabolism and de novo nucleotide 
synthesis. Folate was often covalently attached to a wide variety of drug delivery carriers such as 
liposomes, polymer conjugates, and nano-particulates (Gabizon, Horowitz et al. 1999; Goren, 
Horowitz et al. 2000; Reddy and Low 2000). The high affinity vitamin is a commonly used ligand 
for cancer targeting because folate receptors (FRs) are frequently over-expressed in a range of 
tumor cells (Antony 1992). Folate specifically binds to FRs with a high affinity (KD = ~ 10-9 M), 
enabling a variety of folate derivatives and conjugates to deliver molecular complexes to cancer 
cells without causing harm to normal cells. The FR is a tumor-associated protein, and it can 
actively internalize bound folates and folate-drug conjugates via the natural process of 
















Fig 2-9 Folate mediated targeting 
 
It has been used as a targeting moiety combined with a wide array of drug delivery vehicles 
including liposomes, protein toxins, polymeric NPs, linear polymers, and dendrimers to deliver 
drugs selectively into cancer cells using FR-mediated endocytosis (Benns, Mahato et al. 2002; 
Quintana, Raczka et al. 2002). The attractiveness of folate has been further enhanced by its high 
binding affinity, low immunogenicity, ease of modification, small size, stability during storage, 
compatibility with a variety of organic and aqueous solvents, low cost, and ready availability 





2.3.1.3 Monoclonal Antibody (Herceptin) 
The discovery of antigens that are particularly overexpressed on the surface of cancer cells 
suggests that by using certain monoclonal antibodies (mAbs) to selectively mark tumor cells, 
malignant tissues could be distinguished from normal tissues (Liu, K. M.; Derr et al. 1996). These 
mAbs could be used as vehicles to deliver cytotoxic drugs selectively to tumor cells (Chari, 
Jackel et al. 1995; Chari 1998). The mAb moiety then binds to the antigens on cancer cells and 
the conjugate is internalized via receptor-mediated endocytosis followed by the release of parent 
drug to restore its original activity. 
 
                               
                                                   Fig 2-10 Antibody structure 
 
Monoclonal antibodies are monospecific antibodies that are identical because they are produced 
by one type of immune cell that are all clones of a single parent cell. One of the main applications 
of the monoclonal antibody is in cancer treatment which involves the antibodies to bind only to 
cancer cell-specific antigens and induce an immunological response against the target cancer cell. 




             
Fig 2-11 Monoclonal antibodies for cancer 
(http://www.edinformatics.com/biotechnology/MonoclonalAb.jpg) 
 
It is also possible to design bispecific antibodies that can bind with their Fab (Antigen binding 
fragment) regions both to target antigen and to a conjugate or effector cell. Monoclonal 
antibodies have been generated and approved to treat diseases like cancer, cardiovascular disease, 
inflammatory disease, multiple sclerosis, viral infection etc. It was reported by the 
Pharmaceutical Research and Manufacturers of America, that in 2006, U.S. companies had 160 
different monoclonal antibodies in clinical trials or awaiting approval by Food and Drug 
Administration (FDA).  
Herceptin is one of a new group of cancer drugs called monoclonal antibodies. Herceptin, also 
called trastuzumab, is a monoclonal antibody that interferes with the HER2/neu receptor. It is 
designed to target HER positive cancer cells. They are thought to stop the cancer cells from 
36 
 
growing. The HER2 receptors are proteins that are embedded in the cell membrane and 
communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. 
In some cancers, including breast cancers, the HER2 receptor is defective and stuck in the "on" 
position, and causes breast cells to reproduce uncontrollably, causing breast cancer (Hudis 2007). 
Antibodies are molecules from the immune system that bind selectively to different proteins. 
 
 
                                 Fig 2-12 Monoclonal antibodies for various applications 
 
Trastuzumab is an antibody that binds selectively to the HER2 protein. When it binds to defective 
HER2 proteins, the HER2 protein no longer causes the breast cells to reproduce uncontrollably. 
This increases the survival of people with cancer. However, cancers usually develop resistance to 
trastuzumab. The combination of Trastuzumab with chemotherapy has been shown to increase 
both survival and response rate, in comparison to Trastuzumab alone (Nahta and Esteva 2003). 
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Fig 2-13 Herceptin action with breast cancer cells (http://www.herceptin.com/metastatic/what-
is/how-does-it-work.jsp)  
 
Cells treated with trastuzumab undergo arrest during the G1 phase of the cell cycle, so there is 
reduced proliferation. Also, trastuzumab suppresses angiogenesis by both induction of anti-
angiogenic factors and repression of pro-angiogenic factors. It is thought that a contribution to the 
unregulated growth observed in cancer could be due to proteolytic cleavage of HER2/neu that 
results in the release of the extracellular domain. Trastuzumab has been shown to inhibit 
HER2/neu ectodomain cleavage in breast cancer cells (Albanell, Codony et al. 2003). One of the 
significant complications of trastuzumab is its effect on the heart. Trastuzumab is associated with 
cardiac dysfunction in 2-7% of cases (Seidman, Hudis et al. 2002). Approximately 10% of 
patients are unable to tolerate this drug because of pre-existing heart problems; physicians are 
balancing the risk of recurrent cancer against the higher risk of death due to cardiac disease in this 
population. The risk of cardiomyopathy is increased when trastuzumab is combined with 
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anthracycline chemotherapy (which itself is associated with cardiac toxicity). The other side 
effects are tumor pain, diarrhea, flu-like symptoms, headaches, allergic reactions etc. 
 
                       
      Fig 2-14 Mechanism of action of Herceptin (http://www.roche.com/pages/facets/9/herc2.jpg)  
 
2.3.1.4 Polyunsaturated Fatty Acids 
The polyunsaturated fatty acids (PUFAs) function to target the tumors. Essential fatty acids are 
polyunsaturated fatty acids (PUFAs) that can be obtained only from the diet. There are several 
known PUFAs having 18, 20, and 22 carbons, and 2–6 unconjugated cis-double bonds separated 
by one methylene. Vegetable oils are the source of alinolenic acid (LNA), linoleic acid (LA), and 
arachidonic acid (AA), while cold-water fish is the supply for eicosapentaenoic acid (EPA) and 
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      Fig 2-15 PUFAs 
 
PUFAs have exhibited anticancer activity against CFPAC, PANC-1, and Mia-Pa-Ca-2 pancreatic 
and HL-60 leukemia cell lines, and their antitumor activities have been evaluated in preclinical 
and clinical studies (Wigmore, Ross et al. 1996; Hawkins, Sangster et al. 1998). Moreover, it has 
been shown that PUFAs are taken up greedily by tumor cells, presumably for use as biochemical 
precursors and energy sources (Sauer, Nagel et al. 1986; Sauer and Dauchy 1992). In addition, 
PUFAs are readily incorporated into the lipid bilayer of cells, which results in disruption of 
membrane structure and fluidity (Takahashi, Przetakiewicz et al. 1992; Grammatikos, Subbaiah et 
al. 1994). This has been suggested to influence the chemosensitivity of tumor cells (Diomede and 
J.; Salmona 1993). These findings strongly suggest the benefits in the use of PUFAs for tumor-
targeting drug delivery. For example PUFA–taxoid conjugates have a high potential to become 







2.3.1.5 Hyaluronic Acid 
 
                         
       Scheme 2-3 Hyaluronic Acid 
 
Hyaluronic acid (or hyaluronan) (HA) is a linear, negatively charged polysaccharide, containing 
two alternating units of D-glucuronic acid (GlcUA) and N-acetyl-D-glucosamine (GlcNAc) with 
molecular weight of 105–107. HA is responsible for various functions within the extracellular 
matrix such as cell growth, differentiation, and migration. A wide range of activities can be 
explained by a large number of HA-binding receptors such as cell surface glycoprotein CD44, 
receptor for hyaluronic acid-mediated motility (RHAMM), and several other receptors possessing 
HA-binding motifs, for example, transmembrane protein layilin, hyaluronic acid receptor for 
endocytosis (HARE), lymphatic vessel endocytic receptor (LYVE-1), and also intracellular HA-
binding proteins including CDC37, RHAMM/IHABP, P-32, and IHABP4 (Huang, 
Grammatikakis et al. 2000; Ponta, Sherman et al. 2003). It has been shown that the HA level is 
elevated in various cancer cells (Toole, Wight et al. 2002). The higher concentration of HA in 
cancer cells is believed to form a less dense matrix, thus enhancing the cells motility as well as 
invasive ability into other tissues (Yang, Zhang et al. 1993) and also providing an 
immunoprotective coat to cancer cells (McBride and Bard 1979). It is well known that various 
tumors, for example, epithelial, ovarian, colon, stomach, and acute leukemia, overexpress HA-
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binding receptors CD44 (Day and Prestwich 2002) and RHAMM (Turley, Belch et al. 1993). 
Consequently, these tumor cells show enhanced binding and internalization of HA (Hua, 
Knudson et al. 1993). HA can be coupled with an active cytotoxic agent directly to form a non-
toxic prodrug. Alternatively, a suitable polymer with covalently attached HA and drug can be 
used as a carrier. Direct conjugations of a low molecular weight HA to cytotoxic drugs such as 
butyric acid, paclitaxel, and doxorubicin have been reported. It has been shown that these 
bioconjugates are internalized into cancer cells through receptor-mediated endocytosis, followed 




Peptide-based targeting of tumor-associated receptors is an attractive approach in tumor-specific 
drug delivery because high-affinity sequences can be discovered through screening of 
combinatorial libraries. Recently, numbers of peptides and their conjugates with cytotoxic agents 
that target different cancer cell receptors have emerged as potential tumor-specific 
chemotherapeutic agents. Gastrointestinal (GI) peptides have many physiological functions as 
hormones, neurotransmitters, and growth factors. Each of these peptides usually targets more than 
one receptor. Thus, these peptides and their truncated analogs, possessing appropriate recognition 
properties, could serve as tumor-targeting molecules in combination with cytotoxic agents. 
Somatostatin (SST) is a hormonal neuropeptide existing in two active forms, that is, SST-14 and 
SST-28 with 14 and 28 amino acid residues, respectively. SST-14 and SST-28 interact with cells 
through a minimum of five membrane receptor subtypes (SSTR1–5) inhibiting the secretion of 
various hormones including the growth hormone (GH) also known as somatotropin (Schally 
1988). The SSTR1–5 membrane receptors are expressed at significantly elevated levels in tumor 
cells and possess high binding affinity to somatostatin (Weckbecker, Raulf et al. 1993; Orlando, 
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Raggi et al. 2004). Thus, somatostatin is a good candidate for delivery of cytotoxic agents 
specifically to GI tumor cells. Bombesin (BBN) and the bombesin-like peptide, gastrin-releasing 
peptide (GRP), consist of 14 and 27 amino acid residues, respectively, and have several 
physiological functions as gastrointestinal hormones and neurotransmitters (Schally, Comaru-
Schally et al. 2001).  Moreover, these peptides also function as growth factors and modulate 
tumor proliferation (Cuttitta, Carney et al. 1985). 
 
2.3.2 Passive Targeting and EPR Effect 
Strategies on delivering various drug formulations to cancerous cells make use of the passive 
targeting. Aggressive tumors inherently develop leaky vasculature with 100-800 nm pores due to 
rapid formation of vessels that must serve the fast-growing tumor. This defect in vasculature 
coupled with poor lymphatic drainage serves to enhance the permeation and retention of drug 
formulations within the tumor region. This is often called EPR (Enhanced Permeation and 
Retention) effect (Teicher 2000; Sledge and Miller 2003). Thus the passive targeting uses the 
unique properties of the tumor microenvironment, (1) leaky tumor vasculature, which is highly 
permeable to macromolecules relative to normal tissue and (2) a dysfunctional lymphatic 
drainage system which results in enhanced fluid retention in the tumor interstitial space 
(Matsumura and Maeda 1986; Maeda and Matsumura 1989). 
The EPR effect, related to the transport of macromolecular drugs composed of liposomes, 
micelles, proteinaceous or polymer-conjugated macromolecules, lipid particles, and nanoparticles 
into the tumor, is the hallmark of solid tumor vasculature. These macromolecular species are 
therefore ideal for selective delivery to tumor. The EPR effect has facilitated the development of 
macromolecular drugs consisting of various polymer-drug conjugates (pendant type), polymeric 
micelles, and liposomes that exhibit far better therapeutic efficacy and far fewer side effects than 
the parent low-molecular-weight compounds. Normal tissues contain capillaries with tight 
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junctions that are less permeable to nanosized particles. Passive targeting can therefore result in 
increase in drug concentrations in solid tumors of several-fold relative to those obtained with free 
drugs (Moghimi, Hunter et al. 2001). 
 
 
Fig 2-16 Representation of EPR effect and active targeting for drug delivery to tumors 
(http://www.nature.com/nnano/journal/v2/n12/images/nnano.2007.387-f1.jpg) 
 
The key mechanism for the EPR effect for macromolecules in solid tumors was found to be 
retention, whereas low-molecular weight substances were not retained but were returned to 
circulating blood by diffusion (Noguchi, Wu et al. 1998). It was found that macromolecules 
remain at high levels in the blood circulation; this phenomenon applies to most plasma proteins 
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and biocompatible synthetic polymers or their conjugates. Here, macromolecules are defined as 
larger than 40 KDa. 
 
Factors involved in enhanced vascular permeability in solid tumors (Maeda, Wu et al. 2000) 
 
 
2.4 Drug Delivery Strategies for Cancer Chemotherapy 
2.4.1 Liposomes 
                          
Fig 2-17 Liposome formation (http://www.nanolifenutra.com/images/image_liposome_01.jpg) 
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Liposomes are drug delivery vehicles which were first proposed by Gregoriadis and are 
composition of amphiphilic phospholipids and cholesterol that self-associate into bilayers 
encapsulating an aqueous interior. These may be formulated into small structures (80-100 nm in 
size) that encapsulate either hydrophilic drugs in the aqueous interior or hydrophobic drugs 
within the bilayer. 
Encapsulation of drugs is achieved using a variety of loading methods, most notably the pH 
gradient method used for loading vincristine (Waterhouse, Madden et al. 2005) or the ammonium 
sulfate method for loading doxorubicin (Haran, Cohen et al. 1993). Additionally, the liposome 
surface can be engineered to improve its properties (Allen, Sapra et al. 2002; Sapra and Allen 
2003). So far, the most noteworthy surface modification is the incorporation of polyethylene 
glycol (PEG) which serves as a barrier, preventing interactions with plasma proteins and thus 
retarding recognition by the reticuloendothelial system (RES) (Gabizon, Shmeeda et al. 2003) and 
enhancing the liposome circulation lifetime. However, despite this versatility, there have been 
major drawbacks to the use of liposomes for targeted drug delivery, most notably, poor control 
over release of the drug from the liposome (i.e. the potential for leakage of the drug into the 
blood), coupled with low encapsulation efficiency, manufacturability at the industrial scale and 
poor stability during storage (Soppimath, Aminabhavi et al. 2001; Hans 2002). 
 
2.4.2 Nanoparticles 
In recent decades, there has been increased interest in the use of nanoparticles for drug delivery 
applications. Nanoparticles are colloidal-sized particles, possessing diameters ranging between 1 
and 1000 nm, and drugs may be encapsulated, adsorbed or dispersed in them. A wide variety of 
nanoparticles composed of a range of materials including lipids, polymers and inorganic materials 
have been developed, resulting in delivery systems that vary in their physicochemical properties 
and thus their applications (Liggins and Burt 2002; Gabizon, Shmeeda et al. 2003; Klumpp, 
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Kostarelos et al. 2006). Nanoparticles are used to deliver hydrophilic drugs, hydrophobic drugs, 
proteins, vaccines etc. They can be synthesized by dispersion of polymers and polymerization of 
monomers, which involves solvent extraction/evaporation method, salting out method, dialysis 
method, supercritical fluid spray technique and nanoprecipitation method (Feng SS 2003). 
Among these, the solvent extraction method is the most commonly used one that uses single 
emulsion method and double emulsion method for hydrophobic drugs and hydrophilic drugs 
respectively. 
 
                                        




The solid biodegradable polymeric nanoparticles have certain advantages that makes is an 
attractive area of drug delivery. First, by varying the polymer composition of the particle and 
morphology, one can effectively tune in a variety of controlled release characteristics, allowing 
moderate constant doses over prolonged periods of time (Shive and Anderson 1997). There has 
been variety of materials used to engineer solid nanoparticles both with and without surface 
functionality (Brigger, Dubernet et al. 2002). Perhaps the most widely used are the aliphatic 
polyesters, specifically the hydrophobic poly(lactic acid) (PLA), the more hydrophilic 
poly(glycolic acid) (PGA), and their copolymers, poly(lactide-co-glycolide) (PLGA). The 
47 
 
degradation rate of these polymers, and often the corresponding drug release rate, can vary from 
days (PGA) to months (PLA) and is easily manipulated by varying the ratio of PLA to PGA. 
Second, physiologic compatibility of PLGA and its homopolymers PGA and PLA have been 
established for safe use in humans. These materials have a history of over 30 years in various 
human clinical applications, including drug delivery systems (Langer and Folkman 1976; 
Visscher, Robison et al. 1985). Thus, PLGA nanoparticles can be formulated in a variety of ways 
that improve drug pharmacokinetics and biodistribution to target tissue by either passive or active 
targeting. Also the advantages include targeting drugs to tumors, size availability for intravenous 
injection, reduction in uptake of drugs to RES, improving biodistribution of drugs in the body 
(Kim, Lee et al. 2003).  
The synthesized nanoparticles can be characterized for size and size distribution, surface and bulk 
morphology, surface chemistry, surface charge, physical and chemical status of the drug and drug 
encapsulation efficiency (Feng SS 2003). Recently, nanoparticles using the innovative PLA-
TPGS co-polymer has been used to achieved to deliver anticancer drugs like Paclitaxel, 
Docetaxel, Doxorubicin etc (Mu and Feng 2002; Mu and Feng 2003; Feng, Mu et al. 2004; Win 
and Feng 2005; Zhang and Feng 2006; Zhang, Huey Lee et al. 2007; Pan and Feng 2008; Pan, 
Wang et al. 2008). 
 
2.4.3 Micelles  
Polymeric micelles are formed from spontaneous association of amphiphilic copolymers in an 
aqueous phase. They are characterized by a diameter not exceeding 100 nm. The attractive force 
leading to micellization is based on an interaction between the hydrophobic and electrostatically 
neutral parts of copolymers. Self-assembly starts when the copolymer concentration reaches a 
threshold value known as the critical micelle concentration (CMC). Usually, the CMC of 
amphiphilic copolymers is 1000-fold weaker than that of low molecular weight surfactants (10-6 – 
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10-7 M) (La, Okano et al. 1996). The micelle shape depends on the length of the lipophilic chains 
(Zhang, Yu et al. 1996). The formation of micelles effectively removes the hydrophobic portion 
of the amphiphile from the solution minimizing unfavourable interactions between the 
surrounding water molecules and the hydrophobic groups of the amphiphile. If the amphiphile 
concentration in solution remains above the CMC, micelles are thermodynamically stabilized 
against disassembly. Upon dilution below CMC, micelles will disassemble with the rate of 
disassembly being largely dependent on the structure of amphiphiles and interactions between the 
chains (C. Allen 1999). 
 
                                   




 Currently, polymeric micelles are popular pharmaceutical nanocarriers for the delivery of poorly 
water soluble drugs, which can be solubilized within the hydrophobic inner core of the micelle 
(Bader H 1984; Jones and Leroux 1999). As a result, micelles can substantially improve solubility 
and bioavailability of various hydrophobic drugs (Lukyanov and Torchilin 2004). The small size 
(10-100 nm) of micelles allows for the micelle efficient accumulation in pathological tissues with 
the permeabilized vasculature, such as tumors and infarcts, via enhanced permeation and 
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retention (EPR) effect (Wu, Da et al. 1993; Maeda, Wu et al. 2000; Torchilin 2001). The 
hydrophilic blocks commonly used in drug delivery are polyethers like poly(propylene oxide) and 
PEG (Vakil and Kwon 2005) with a molecular mass comprised between 1 and 15 KDa (Torchilin 
2004). Other hydrophilic polymers may be used (Torchilin, Trubetskoy et al. 1995). Polymeric 
nanocarriers must have a size larger than 42-50 KDa in order to prevent their elimination by the 
glomerular excretion of kidneys (Seymour, Duncan et al. 1987). Various hydrophobic anticancer 
agents including paclitaxel (Nakayama M 2006) and docetaxel (Le Garree D. Gori S 2005) were 
incorporated into the hydrophobic core of polymeric micelles. These drugs can be chemically 
conjugated to macromolecules.  
 
2.4.4 Microspheres 
Microspheres are prepared by commonly used methods such as solvent evaporation and spray 
drying. It is also used for microencapsulation methods (Vasir, Tambwekar et al. 2003). Mostly 
the polymeric microspheres are synthesized. In the solvent evaporation method, spherical droplets 
can be formed by dispersing hydrophobic monomers in aqueous solution or hydrophilic 
monomers in an organic phase. Usually, double emulsion method is used. In this, the first water 
in oil emulsion, in which drug is dispersed in water, is dispersed in another aqueous medium to 
get the final oil in water emulsion. Microspheres can protect the drug molecules against 
degradation, control their release after administration and facilitate their passage across biological 
barriers. Using a double emulsion solvent evaporation method, some researchers have achieved a 
constant release of drug from the micelles after initial burst (Yang YY 2000). Recently, 
polymeric microspheres are synthesized using PMMA polymer, which are useful in tattoo 




                             





Polymer paste in chemotherapeutic are used to maximize local drug level in tumor environment 
but minimize systemic exposure to normal tissues during local administration or direct injection 
of chemotherapeutic agents. The polymer paste is prepared by loading the chemotherapeutic 
agents like paclitaxel. The base component used is PCL that has low melting point 50-60° C and 
biodegradation life time of 6-9 months in vivo (Pitt, Gratzl et al. 1981). The paste is also said to 
suppress tumor growth by intra tumoral injection of the paste and due to its slow release (Jackson, 
Gleave et al. 2000). 
 
2.5 Prodrugs 
2.5.1 Concept of Prodrug 
A Prodrug is a form of a drug that remains inactive during its delivery to the site of action and is 
activated by the specific conditions in the targeted site as illustrated in Fig 2-21. The conjugation 
of a drug with a polymer is called ‘polymeric prodrug’. Albert and his coworkers were the first 
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ones to suggest the concept of prodrug approach for increasing the efficiency of drugs in 1950. 
The prodrug approach has been one of the most promising means of site-specific drug delivery 
(Takakura and Hashida 1995). Currently, 5-7% of the drugs approved worldwide can be 
classified as prodrugs and approximately 15% of all new drugs approved in 2001 and 2002 were 
prodrugs (Rautio, Kumpulainen et al. 2008). Here, antitumor drug-macromolecular conjugates are 
called as ‘macromolecular prodrugs’. 
 
 
Fig 2-21 An illustration of the Concept of Prodrug (Stella and Nti-Addae 2007) 
 
 
2.5.2 Why Prodrugs? 
The prodrugs are developed mainly to overcome the drawbacks of the drugs such as site 
specificity, permeability, resistance and hydrophobicity. The use of prodrugs can be reasoned due 
to its advantages that include (1) an increase in water solubility of low soluble or insoluble drugs, 
and thus enhancement of drug bioavailability, (2) protection of drug from deactivation and 
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preservation of its activity during circulation, transport to targeted organ or tissue and 
intracellular trafficking, (3) an improvement in pharmacokinetics, (4) a reduction in antigenic 
activity of the drug leading to a less pronounced immunological body response, (5) the ability to 
provide passive or active targeting of the drug specifically to the site of its action, (6) the 
possibility to form an advanced complex drug delivery system, which in addition to drug and 
polymer carrier, includes several other active components that enhance the specific activity of the 
main drug. 
 
2.5.3 Classification of Prodrugs 
Prodrugs are classified mainly into 2 types 
(1) Carrier-linked prodrugs  
The Carrier-linked prodrugs are drugs that are attached through a metabolically labile chemical 
linkage to another molecule designated as the ‘promoiety’. The promoiety alters the physical 
properties of the drug to increase water or fat solubility or provide site directed delivery. The 
Carrier-linked prodrugs are further divided into (1) bipartate, (2) tripartate and (3) mutual 
prodrugs. The bipartate prodrug is composed of one carrier group attached to the drug (eg. 
Prednisolone, Benzocaine etc) and the tripartate prodrug is composed of carrier group attached to 
the drug via linker (eg. Bacampicillin, Pivampicillin etc). The mutual prodrugs are composed of 2 
drugs linked together (eg. Sultamacillin) (D. Bhosle 2006). The advantages of the carrier-linked 
prodrugs are increased absorption, injection site pain relief, elimination of unpleasant taste, 
decreased toxicity, decreased metabolic inactivation, increased chemical stability and prolonged 
or shortened action. 
(2) Bioprecursor prodrugs 
Bioprecursors are those metabolized into new compound that may itself be active or further 
metabolized into an active metabolite (eg. Amine to aldehyde to carboxylic acid). They rely on 
53 
 
oxidative and reductive activation reactions unlike the hydrolytic activation of carrier-linked 
prodrugs. The oxidative activation reactions are N- and O- Dealkylation (Phenacetin), Oxidative 
Deamination (Cyclophosphamide), N-Oxidation (Pralidoxime chloride) and Epoxidation 
(Carbamazepine). The reductive activation reactions are Azo Reduction (Sulfasalazine), 
Sulfoxide Reduction (Suldinac), Disulfide Reduction (Thiamin), Bioreductive Alkylation 
(Mitomycin C) and Nitro Reduction. 
 
2.5.4 Polymer-Drug Conjugation 
The rationale for polymer conjugation is the possibility to prolong the half-life of therapeutically 
active agents by increasing their hydrodynamic volume and hence decreasing their excretion rate. 
Futher more, polymer chains can prevent the approach of antibodies, proteolytic enzymes or cells 
on conjugated molecules, an effect obtained by the steric hindrance of polymer strands. 
Immunogenicity is likely to be one of the most serious problems, especially when dealing with 
heterologous proteins that commonly cause adverse response when recognized as non-self by the 
body immune system. The prevention of immunogenicity can be attributed to the shielding effect 
of polymeric chains surrounding the protein. This steric hindrance prevents interaction of 
antibodies or degrading enzymes with the protein. In general, the conjugation of hydrophilic 
polymers deeply changes the behavior of the parent (free) compound both in vitro and in vivo. 
This change happens with both proteins and low molecular weight agents. Some advantages are 
(1) increased water solubility, (2) enhanced bioavailability and prolonged plasma half-life, (3) 
protection towards degrading enzymes, (4) prevention or reduction of aggregation, 
immunogenicity and antigenicity and (5) specific accumulation in organs, tissues and cells, by 
active or passive targeting (Maeda, Wu et al. 2000). 
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The difficulties encountered in the development of successful conjugates of low molecular weight 
drugs can be attributed to the vast number of chemical and biological factors that has to be taken 
into consideration namely, 
 Conjugate features – eg. Size, polydispersity, solubility, hydrophilic/lypophilic balance, 
stability, biodegradability,  drug loading, free drug amount as impurity, mechanism of 
drug release 
 In vivo behavior – eg. Biodistribution, pharmacokinetics, interaction with the blood 
components and cells, intracellular trafficking, specific targets, metabolism. 
 
 
Fig 2-22 Polymer-drug conjugates (Duncan 2006) 
 
Usually, a covalent and strategically positioned linkage with the polymer prevents the activity of 
small drugs. To ensure drug release, several methods have been developed primarily based on 
55 
 
either hydrolytically unstable bond or enzymatically labile spacers between the drug and the 
polymer. To maximize the outcomes and better tailor the polymer conjugation, a number of 
different polymers and chemical approaches were also developed, yielding a selection of new 
structures like dendrimers (Tomalia DA 1985), dendronized polymers, graft polymers, block 
copolymers (Pechar, Ulbrich et al. 2000), branched polymers (Stiriba, Kautz et al. 2002), 
multivalent polymers, stars and hybrid glycol and peptide derivatives. 
 
2.5.5 Ringsdorf model 
 
 
                                             Helmut Ringsdorf 
 
The Ringsdorf model proposed in 1975 by Helmut Ringsdorf, describes the ideal polymeric 
prodrug model for the polymer-low molecular weight drug conjugates. The spacer should assist 
mild drug fixation. The spacers are classified as permanent and temporary spacer. The permanent 
spacers are those that interfere in the biological activity of the drug and temporary spacers are 
those that do not interfere in the biological activity of the drug.  
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                        Fig 2-23 Ideal polymeric prodrug model (Pasut 2007) 
 
The targeting moiety of the Ringsdorf model is used for specific resorption at the biological target 
cells. The solubilizing residue of the model functions in adding non-toxic, non-immunogenic and 
soluble character to polymer chain.  
 
2.5.6 Design of Polymeric Prodrugs 
Design of polymeric prodrugs is one of the approach developed for improved use of drugs for 
therapeutic applications. A prodrug is a chemical entity of an active parent drug with altered 
physico-chemical properties (Hoste, De Winne et al. 2004). The most complete realization of the 
prodrug approach is possible by the use of an advanced type of prodrug- the drug delivery 
system. This system can be constructed to target a desired organ, its cells or organelles as well as 
to release a specific amount of the drug at desired times. The polymer prodrug conjugate can also 
increase aqueous solubility, enhance biodistribution and retain the inherent pharmacological 





Fig 2-24 Incorporation of spacers in prodrug conjugation 
 
There are 3 major types of polymeric prodrugs currently used (David, Kopeckova et al. 2004). 
The first type of prodrug are broken down inside cells to form active substance or substances. The 
second type of prodrug is usually the combination of two or more substances. Under specific 
intracellular conditions, these substances react forming an active drug. The third type of prodrug, 
targeted drug delivery systems, usually includes three components, a targeting moiety, a carrier 
and one or more active components. The targeting ability of the delivery system depends on the 
several variables including receptor expression, ligand internalization, choice of antibody, 
antibody fragments or no-antibody ligands and binding affinity of the ligand (Allen 2002). 





    
Fig 2-25 Polymeric prodrug with targeting agent (Jayant Khandare 2006) 
 
 
2.5.7 Critical Aspects of Polymer Conjugation 
The critical aspects of polymer conjugation includes the structure-activity relationship (SAR) of 
conjugation, steric hindrance, enhanced reactivity of polymers by incorporation of spacers and 
targeting of polymeric drugs that include active and passive targeting. The SAR means the effect 
of a drug, in its conjugated form, on an animal, plant or the environment as it relates to its 
molecular structure. Very few reports suggest the differences in SAR due to variations of the 
conjugated sites of a drug with the polymer. Such studies are possible if a drug candidate has 
different sites for conjugation and their activity mechanisms are established. The drug, 
Methotrexate (MTX), is an ideal candidate for these studies, as it has two –COOH groups 
available for the covalent linkage with the polymeric carrier. The drug delivery is relatively 
maintained when the gamma-carboxyl is chemically modified, whereas the alpha-carboxyl has 
much less bulk tolerance (Rosowsky, Forsch et al. 1981). Recently, design and synthesis of 
dextran-peptide-MTX conjugates for tumor-targeted delivery of chemotherapeutics via the 
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mediation of matrix metalloproteinase II and matrix metalloproteinase IX was reported (Chau, 
Tan et al. 2004). Steric hindrance describes how molecular groups interfere with other groups in 
the structure or other molecules during chemical conjugation. This effect is due to the interaction 
of the molecules as dictated by their shape and/or spatial relationships. The macroscale 
architecture of polymers causes steric hindrance for covalent conjugation with drugs in general, 
and large peptide molecules in particular. Steric hindrance drives chemical conformations and 
may affect the chemical conjugation with bulkier unstable molecules. Therefore, a conjugation 
reaction involving polymers, peptides and unstable molecules requires methodologies to reduce 
this effect. The most preferred method to decrease steric hindrance has been to alter the synthesis 
approach either by incorporating a spacer arm or by increasing the reactivity of the polymer or 
biomolecules (Khandare, Kolhe et al. 2005). During bioconjugation, high molecular weight 
biomolecules and polymers exhibit steric hindrance for the reactions. This is especially true for 
the linear polymers, in general, and dendrimers in particular. Therefore, the hindrance must be 
reduced either by incorporation of the spacer molecule or by increasing the reactivity of the 
bioconjugating moiety. Instead of conjugating two large molecules directly, one may be reacted 
first with small, reactive spacer arm moiety to increase the final reactivity. Further, the resultant 
conjugate can be coupled with the second molecule (Khandare, Kolhe et al. 2005). Crowding of 
functional groups and steric hindrance may lead to lower conjugate ratios with unreacted 
polymers. The reactivity of functional polymers to couple with other biomolecules, which may be 
low, could be enhanced by first conjugating the polymer with reactive bis functional molecules. 
The resulting polymer–spacer conjugate moiety often enhances the reactivity and decreases steric 
hindrance for further coupling with drugs or biomolecules (Khandare, Kolhe et al. 2005). 
Commonly used as spacers for conjugating polymers with drugs and other biomolecules include 
a-amino acids such as glycine, alanine, and serine. Polymer carriers used for conjugation with 
anticancer drugs are often linked by polypeptides (Li 2002). Most of the conjugation methods 
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involve the use of spacers, which provide chemical flexibility for coupling biological compounds 
to the polymers. Conjugation of low molecular weight drugs to high molecular weight carriers 
results in high molecular weight prodrugs, which substantially changes the mechanisms of 
cellular drug entrance. While small molecular weight drugs enter cells primarily by diffusion, 
high molecular weight drugs are internalized mainly by endocytosis. 
 
2.5.8 Characteristics of Prodrugs 
In recent years, numerous prodrugs have been designed and developed to overcome barriers to 
drug utilization, such as low oral absorption properties, lack of site specificity, chemical 
instability, toxicity, bad taste, odour, pain at application site, etc. It has been suggested that the 
following characteristics of a prodrug must be improved for site-specific drug delivery. 
(1) The prodrug must be readily transported to the site of action 
(2) The prodrug must be selectively cleaved to the active drug utilizing special enzymatic 
profile of the site 
(3) Once the prodrug is selectively generated at the site of action, the tissue must retain the 
active drug without further degradation. 
 
2.5.9 Mechanism of Action 
Macromolecules normally cannot enter cells by passive diffusion across the plasma membrane. 
The general mechanism whereby they pass the cell membrane is endocytosis. A macromolecule, 
when dissolved in the extracellular fluid can enter a cell at a relatively slow rate. This process is 
called ‘fluid-phase endocytosis’. Macromolecular prodrugs using carriers without any special 
affinity to tumor cells are considered to be endocytosed by this mechanism. In ‘adsorptive 
endocytosis’, macromolecules bound to the plasma membrane are internalized at rates usually 
faster than those by fluid-phase endocytosis. Tumor cells may endocytose cationic 
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macromolecular prodrugs, following adsorption on the plasma membrane by electrostatic force 
by this process. Actively targeted macromolecular prodrugs with carriers of glycoproteins, 
hormones, lectins, etc. are rapidly and effectively internalized by adsorptive or receptormediated 
endocytosis, which occurs via coated pits. In conjunction with drug release problems, the rate and 
extent of endocytosis of macromolecular prodrugs are of particular importance to their 
pharmacological efficacy. The pharmacological activity of macromolecular prodrugs requires the 
release of free drugs by chemical and/or enzymatic reactions from the conjugate. In terms of drug 
release, the stability of the linkage between the carrier and the drug, and the site of regeneration 
of the free drug from the conjugate are important factors. Since the site of action of most 
antitumor drugs, such as nuclei, is located in the intracellular space of tumor cells, the therapeutic 
efficacy of a macromolecular prodrug greatly depends on where the free drugs are released. The 
most well-known concept for the mechanism of action of macromolecular prodrugs is the 
principle of a ‘lysosomotropic’ delivery which was advocated more than two decades ago by 
Trouet et al. (Trouet A 1972) for a DNA-daunorubicin complex. Another mechanism for the intra 
lysosomal drug release involves the low pH in the lysosomal milieu. In this approach, free active 
drugs are generated from the conjugates by a chemical reaction under the acidic condition. In 
order to elucidate the mechanism of action of macromolecular produrgs cellular interactions and 
in vitro antitumor activities of mitomycin C-dextran conjugates have been studied in a cell culture 
system (Matsumoto, Yamamoto et al. 1986). Macromolecular prodrugs endocytosed by the tumor 
cells also may have exhibited cytotoxicity, but contribution of this mechanism seem to be 
minimal because drug release is slower and mitomycin C is unstable (Beijnen JH 1985) at a low 






Fig 2-26 Mechanism of action of polymer drug conjugate (Duncan 2006) 
 
Hydrophilic polymer–drug conjugates administered intravenously can be designed to remain in 
the circulation. The clearance rate of the conjugates depends on conjugate molecular weight, 
which governs the rate of renal elimination. Drug that is covalently bound to the polymer by a 
linker, that is stable in the circulation, is largely prevented from accessing normal tissues 
(including sites of potential toxicity), and biodistribution is initially limited to the blood pool. The 
blood concentration of drug conjugate drives tumor targeting due to the increased permeability of 
angiogenic tumor vasculature (compared with normal vessels), providing the opportunity for 
passive targeting due to the enhanced permeability and retention effect (EPR effect). Through the 
incorporation of cell-specific recognition ligands it is possible to bring about the added benefit of 
receptor-mediated targeting of tumor cells. It has also been suggested that circulating low levels 
of conjugate (slow drug release) might additionally lead to immunostimulation. On arrival in the 
tumor interstitium, polymer-conjugated drug is internalized by tumor cells through either fluid-
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phase pinocytosis (in solution), receptor-mediated pinocytosis following non-specific membrane 
binding (due to hydrophobic or charge interactions) or ligand–receptor docking. Depending on 
the linkers used, the drug will usually be released intracellularly on exposure to lysosomal 
enzymes. The active or passive transport of drugs such as doxorubicin and paciltaxel out of these 
vesicular compartments ensures exposure to their pharmacological targets. Intracellular delivery 
can bypass mechanisms of resistance associated with membrane efflux pumps such as p-
glycoprotein. Non-biodegradable polymeric platforms must eventually be eliminated from the 
cell by exocytosis. Rapid exocytic elimination of the conjugated drug before release would be 
detrimental and prevent access to the therapeutic target.  
 
2.5.10 Bioconversion of Prodrugs 
Conversion of the prodrug to the parent drug at the target site is critical for the prodrug approach 
to be successful. Typically, activation involves metabolism by enzymes that are distributed 
throughout the body (Williams 1985; Rooseboom, Commandeur et al. 2004). Many prodrugs 
contain an ester bond, which is formed by derivatizing a phenolic, hydroxyl, or carboxyl group 
present in the drug molecule. When the ester bond of the prodrug is cleaved, the active drug is 
released. The cleavage of the ester bond typically occurs through hydrolysis or oxidation. The 
most important esterases that catalyze hydrolyses of prodrugs include carboxylesterase, 
acetylcholinesterase, butyrylcholinesterase, paraoxonase, and arylesterase. Oxidation cleavage of 
ester-based prodrugs is catalyzed by cytochrome P450s. Since esterases in particular are widely 
distributed throughout the body and therefore the ester bond is quite labile in vivo, many ester-
based prodrugs have been developed (Beaumont, Webster et al. 2003). In many cases, these 
prodrugs were designed to improve the oral bioavailability of drugs (Wang, Jiang et al. 1999; 





Fig 2-27 Selective release of active drugs in regions of low oxygen concentration in tumors 
(Scientific Yearbook 2001-02; Pg 36) 
 
 
There is a problem with the ester prodrugs is the difficulty in predicting their rates of 
bioconversion and, thus, their pharmacological or toxicological effects. This is particularly a 
problem when one is trying to use animal data to predict the prodrug’s bioconversion in human. 
Species differences can generally result from the existence of different types of esterases in 
biological media and differences in their respective substrate specificities (Liederer and Borchardt 
2005). Even within one species, the rate of hydrolysis is not always predictable for the same 
reasons (Hosokawa, Endo et al. 1995). Additionally, bioconversion can be affected by various 
factors such as age, gender and disease. The enzymes involved in the bioconversion of ester 
prodrugs are Esterases, which is classified into Esterases A, which includes paraoxonase, and 
Esterases B, that includes carboxylesterase, acetylcholinesterase, cholinesterase and human 
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valacyclovirase. The factors affecting the bioconversion of ester prodrugs are species differences, 













Fig 2-28 Enzymes involved in biotransformation of prodrugs 
 
 
2.6 Vitamin E TPGS, an amphiphilic polymer 
2.6.1 Structure and Properties 
 
 




D-α-tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS or TPGS) is a water 
soluble derivative of natural vitamin E and prepared by esterification of d-α-tocopheryl acid 
succinate with polyethylene glycol 1000. It is an amphiphilic macromolecule comprising of 
hydrophilic polar head and a lypophilic alkyl tail. Its molecular weight is approximately 1542 Da. 
The hydrophile/lipophile balance (HLB) of TPGS is ~13. It is basically a waxy solid appearing 
white to light brown in color with a melting point approximately 37-41°C. It is stable in air as 
well. It is used an effective emulsifier as well as a good solubilizer due to its bulky nature and 
larger surface area (Fisher 2002). TPGS has found wide utility in pharmaceutical formulations as 
follows. 
 Improving drug bioavailability 
 Surfactant properties enhance solubilization of poorly water soluble drugs 
 Stabilization of the amorphous drug form 
 Enhances drug permeation by P-glycoprotein efflux inhibition 
 Emulsion vehicle 
 Functional ingredient in self-emulsifying formulations 
 Thermal binder in melt granulation/extrusion processing 
 Reducing drug sensitivity on skin or tissues 
 Carrier for wound care and treatment 
 Water-soluble source of vitamin E 
 
2.6.2 Absorption/Bioavailability Enhancer  
TPGS has received increased attention in the literature for its ability to enhance the absorption of 
several drugs that have otherwise poor bioavailability. Sokol et al. in 1991 clinically 
demonstrated that TPGS can enhance absorption of the highly lipophilic drug cyclosporin, which 
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is used for immunosuppressive therapy to manage rejection of transplanted organs. This is a 
crucial finding for organ transplant recipients. Due to the impaired absorption of cyclosporine, 
massive doses are required to achieve therapeutic blood plasma concentrations. The study showed 
that TPGS provides a substantial improvement of cyclosporine absorption and a significant 
reduction of the high cost of immunosuppressive therapy. While Sokol originally suggested that 
the increased bioavailability was due to micelle formation enhancing the solubility, others have 
since provided evidence supporting enhanced permeability due to P-glycoprotein (P-gp) 
inhibition (Croockewit, Koopmans et al. 1996; Dintaman and Silverman 1999). While many of 
the examples of TPGS use are poorly water soluble drugs there are also examples of using TPGS 
with poorly permeable drugs that are water soluble (Prasad, Puthli et al. 2003). Many studies have 
been conducted to evaluate the mechanism by which TPGS affects bioavailability. Its action is 
attributable to its ability to improve solubility through micelle formation and through enhancing 
permeability across cell membranes by inhibition of multi-drug efflux pump P-gp. For oral 
delivery, TPGS enhances drug efficacy by improving the solubilization or emulsification of the 
drug in the finished dosage form and through formation of a self-emulsifying drug delivery 
system in the stomach which may be due to TPGS, which improves the permeability of a drug 
across cell membranes by inhibiting P-glycoprotein and thus enhance absorption of a drug 
through intestinal wall and into the bloodstream. It can act as a reversal agent of P-gp mediated 
multidrug resistance and inhibit P-gp substrate drugs transport (Dintaman and Silverman 1999). 
TPGS is more effective P-gp inhibitor than many related excipients with surfactant properties 
such as cremophor EL, Tween 80, Pluronic P85 and PEG 300. However, it is significantly less 
potent than other clinically tested pharmacologically active compounds such as cyclosporine, 





2.6.3 Solubilization of Poorly Water Soluble Compounds 
It is estimated that over 40% of new drug entities are poorly water soluble. Some drug delivery 
systems that can utilize the solubilizing ability of TPGS are solid dispersions, self-emulsifying 
drug delivery systems, self-microemulsifying drug delivery systems, spray drying and others. 
Much work has been done to investigate the effect of TPGS on the aqueous solubility of poorly 
water soluble drugs. It was shown that TPGS can enhance the solubility and bioavailability of 
poorly absorbed drugs by acting as a carrier in drug delivery systems, thus providing an effective 
way to improve the therapeutic efficiency and reduce the side effects of the anticancer drugs 
(Fisher 2002; Youk, Lee et al. 2005). One of the early discoveries on the solubilizing potential of 
TPGS is attributable to the work of Ismailos et al. who followed up on the discovery that TPGS 
can be co-administered with cyclosporine A resulting in dramatic decrease in the dosage required 
of this costly drug (Ismailos 1994). Also, it was found that TPGS improves the solubility of the 
poorly water soluble drug amprenavir (Yu, Bridgers et al. 1999). Below the critical micelle 
concentration, there is no increase in solution. A more recent application involves taxoids which, 
while important for their chemotherapeutic action, are poorly water soluble and difficult to 
administer in oral formulation. TPGS is one of the best excipients in which taxoids are soluble. It 
shows excellent solubilization properties for oral formulation containing paclitaxel and TPGS 
(Varma and Panchagnula 2005). 
 
2.6.4 Controlled Delivery Applications 
TPGS can be a good emulsifier or surfactant in fabricating nano/microparticles. TPGS emulsified 
PLGA nanoparticles fabricated by a modified solvent extraction/evaporation method have narrow 
polydispersity range from 0.005-0.045 and size around 300-800 nm. TPGS can also achieve 
emulsification efficiency as the amount of TPGS needed in the fabrication process was only 
0.015% (w/w), which was far less than 1% for PVA needed in similar process (Mu and Feng 
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2002; Mu and Feng 2003). Mu and Feng also found that TPGS could be a good component of the 
polymeric matrix material in fabrication of PLGA nanoparticles. Feng et al found that 
nanoparticles coated with TPGS eliminated the side effects caused by human intestinal epithelia 
cells and cancer cell mortality (Feng, Mu et al. 2004). The polymeric nanoparticles, in which 
active agent is dissolved, entrapped, encapsulated, adsorbed, attached or chemically coupled, are 
an exciting new area of research. Here the co-polymerization of TPGS with a polymer such as 
PLZ, PCL or PLGA can improve the emulsification efficiency, drug encapsulation efficiency and 
enhance the cellular uptake of the nanoparticles, thereby increasing the therapeutic effect. These 
have been demonstrated on microencapsulated paclitaxel (Mu and Feng 2003; Zhang and Feng 
2006). TPGS is also said to be a more effective and safer emulsifier than PVA with easier usage 




2.6.5 Non-Oral Delivery Applications 
2.6.5.1 Nasal/Pulmonary Delivery 
Use in nasal/pulmonary delivery formulations show that TPGS increases the immune response 
toward diphtheria toxoid loaded poly(caprolactone) microparticles (Somavarapu, Pandit et al. 
2005). TPGS has also recently been found to be an adjuvant for nasally applied anti-tetanus 
toxoid, anti-diphtheria toxoid in mice (Alpar, Eyles et al. 2001). TPGS, which has good 
physiological compatibility with the mucous membrane surface, serves as wetting agent to 
smooth the membrane surfaces, which in turn delimit the flow channels. In this formulation, 
TPGS plays an important role not only as a surface-active agent but also as an emulsifier [US 




2.6.5.2 Ophthalmic Delivery 
It describes many drug delivery systems in which TPGS is compatible and has shown utility. 
These drug delivery systems include: bioadhesive hydrogels, liposomes, nanoparticles, and the 
use of excipients with solubility enhancing properties (Bourlais, Acar et al. 1998). 
 
2.6.5.3 Parental Delivery 
Here, TPGS has been used in clinical trials and has been the subject of a pharmacokinetic study 
(Lissianskaya 2004; Hanauske 2005). TPGS is included in the formulations of taxane analogues 
to improve their solubility. It may also have some therapeutic value against cancer cells as it has 
been found to induce apoptosis and inhibit the growth of human lung carcinoma cells implanted 
in nude mice (Youk, Lee et al. 2005). 
 
2.6.5.4 Dermal Delivery 
Dermal applications can use TPGS’s surface active properties to improve the surface wetting of 
films with skin. Incorporating TPGS in hot-melt extruded hydroxypropylcellulose and 
polyethyleneoxide films resulted in nearly doubling the adhesive strength of the films (Repka and 
McGinity 2001). This result may indicate that TPGS could be an important additive in 
transdermal/transmucosal or wound care systems. It may also serve as a human skin penetration 
enhancer was shown for radiolabeled hydrocortisone. It also has good bioadhesive properties. 
 
2.6.6 Anti-cancer Activity 
TPGS is PEG 1000- conjugates to derivative of α-tocopheryl succinate (TOS) while TOS is a 
succinyl derivative of vitamin E and has been found to have anticancer properties against 
leukemia, melanomas, breast, colorectal, malignant brain, lung and prostate cancers (Neuzil, 
Weber et al. 2001; Yu, Liao et al. 2001). TOS differs from other vitamin E derivatives in that 
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TOS itself does not act as an antioxidant (Neuzil 2002). In xenograft experiments, TOS 
suppressed tumor growth, both alone and in combination with other anticancer agents (Barnett, 
Fokum et al. 2002; Weber, Lu et al. 2002). The anticancer activity of TOS is mediated by its 
unique apoptosis-inducing properties which appear to be mediated through diverse mechanisms 
involving the generation of reactive oxygen species (ROS) (Wang, Witting et al. 2005). ROS can 
damage DNA, proteins and fatty acids in cells resulting in apoptotic cell death depending on the 
strength and duration of ROS generation. It has poor water solubility but its conjugation to PEG 
makes it water soluble. 
 
 
2.7 Doxorubicin, an anti-cancer drug 
2.7.1 Structure and Properties 
 
    
Scheme 2-5 Structure of Doxorubicin 
 
Doxorubicin (trade name Adriamycin; also known as hydroxydaunorubicin) is a drug used in 
cancer chemotherapy. It is an anthracycline antibiotic, closely related to the natural product 
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daunomycin, and like all anthracyclines it intercalates DNA. It is commonly used in the treatment 
of a wide range of cancers, including hematological malignancies, many types of carcinoma, and 
soft tissue sarcomas. The drug is administered in the form of hydrochloride salt intravenously. It 
is photosensitive and it is often covered by an aluminum bag to prevent light from affecting it. Its 
IUPAC name is (8S,10S)-10-(4-amino-5-hydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-
6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione. It has 
a molecular mass of 543.52 g/mol with 5% oral bioavailability and 12-18.5 hrs half-life. 
Doxorubicin (DXR) is a 14-hydroxylated version of daunorubicin, the immediate precursor of 
DXR in its biosynthetic pathway. Daunorubicin is more abundantly found as a natural product 
because it is produced by a number of different wild type strains of streptomyces. In contrast, 
only one known non-wild type species, streptomyces peucetius subspecies cesius ATCC 27952, 
was initially found to be capable of producing the more widely used doxorubicin (Lomovskaya, 
Otten et al. 1999). This strain was created by Arcamone et. al in 1969 by mutating a strain 
producing daunorubicin, but not DXR, at least in detectable quantities (Arcamone, Cassinelli et 
al. 1969).  
 
2.7.2 Mechanism of Action 
The action mechanism of doxorubicin is complex and still somewhat unclear, though it is thought 
to interact with DNA by intercalation (Fornari, Randolph et al. 1994). Doxorubicin is known to 
interact with DNA by intercalation and inhibition of macromolecular biosynthesis (Momparler, 
Karon et al. 1976). This inhibits the progression of the enzyme topoisomerase II, which unwinds 
DNA for transcription. Doxorubicin stabilizes the topoisomerase II complex after it has broken 
the DNA chain for replication, preventing the DNA double helix from being resealed and thereby 
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stopping the process of replication. The planar aromatic chromophore portion of the molecule 
intercalates between two base pairs of the DNA, while the six-membered daunosamine sugar sits 
in the minor groove and interacts with flanking base pairs immediately adjacent to the 
intercalation site, as evidenced by several crystal structures (Pigram, Fuller et al. 1972; Frederick, 
Williams et al. 1990). 
     




2.7.3 Limitations and Side Effects 
Although doxorubicin is one of the most effective chemotherapeutic agents with most frequently 
usage, its clinical use is limited due to the acute side-effects of doxorubicin that includes nausea, 
vomiting, and heart arrhythmias. It can also cause neutropenia (a decrease in white blood cells), 
as well as complete alopecia (hair loss). When the cumulative dose of doxorubicin reaches 
550 mg/m², the risks of developing cardiac side effects, including congestive heart failure, dilated 
cardiomyopathy, and death, dramatically increase (Petit 2004). Doxorubicin cardiotoxicity is 
characterized by a dose-dependent decline in mitochondrial oxidative phosphorylation. Reactive 
oxygen species, generated by the interaction of doxorubicin with iron, can then damage the 
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myocytes (heart cells), causing myofibrillar loss and cytoplasmic vacuolization. Additionally, 
some patients may develop Palmar plantar erythrodysesthesia, or, "Hand-Foot Syndrome," 
characterized by skin eruptions on the palms of the hand or soles of the feet, characterized by 
swelling, pain and erythema. Due to these side effects and its red color, doxorubicin has earned 
the nickname "red devil" or "red death". Doxorubucin can also cause reactivation of Hepatitis B. 
Besides these side effects, it has another limitation namely the multi-drug resistance (MDR). 
Multi-drug resistance in the cancer treatment by overexpression of MDR transporter proteins such 
as P-gp and multidrug resistance associated protein (MRP). These are expressed in many tumor 
cells like liver, kidney and colon cells, as well as malignant cells. Doxorubicin is a substrate of P-
gp, that results in short half-life in circulation and low therapeutic efficiency (Krishna and Mayer 
2000). 
 
2.7.4 Systems for Delivery of Doxorubicin 
Various researchers have studied ways to target doxorubicin delivery to cancer tissues or to 
diminish the side effects. To overcome the limitations and side effects of doxorubicin, different 
formulations have been developed successfully. The doxorubicin can be delivered to the cancer 
cells into the body by the drug delivery systems that include nanoparticles, prodrugs, micelles, 
liposomes etc. The nanoparticles, especially polymeric nanoparticles, are said to have better 
delivery of doxorubicin to the cancer cells due to its smaller size and encapsulation of drug by the 
polymer, which result in sustained release (Zhang, Huey Lee et al. 2007). Over the past decade, 
polymeric micelles have received much attention to deliver anticancer drugs. Micelles are used 
for improving the delivery of doxorubicin due to its size, which is less than 100 nm, and escape 
from renal exclusion and reticulo-endothelial system giving them enhanced vascular 
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permeability. For DOX, biodegradable polymeric micelles were extensively utilized for passive 
targeting to solid tumors (Yokoyama, Kwon et al. 1992; Yoo and Park 2001; Yoo, Lee et al. 
2002) and active targeting as well (Yoo and Park 2004). Prodrugs are developed to deliver the 
drug with reduced side effects by increasing the half-life of the drug. The prodrugs developed 
include DOX-GA3 prodrug (Houba, Boven et al. 2001), HPMA-doxorubicin conjugate (Shiah, 
Dvorak et al. 2001), doxorubicin-PEG-folate conjugate, doxorubicin-cephalosporin prodrug 
(Veinberg, Shestakova et al. 2004), N-(phenylacetyl) doxorubicin (Zhang, Xiang et al. 2006), 
PEG-doxorubicin conjugates (Rodrigues, Beyer et al. 1999; Veronese, Schiavon et al. 2005). 
Doxorubicin loaded liposomes have enhanced efficiency in some solid tumors compared with 
free doxorubicin, because they passively target solid tumors through the enhanced permeability 
and retention effect, resulting in increased drug payloads delivered to tumors (Gaber MH 1995; 
Laginha, Verwoert et al. 2005). 
 
2.8 Folic Acid 
2.8.1 Structure and Properties of Folic Acid 
    
Scheme 2-6 Structure of Folic Acid 
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Folic acid is also known as Vitamin B9 or Folacin. Folate is said to be the naturally occurring 
form of folic acid. Here, folic acid and folate are forms of the water-soluble Vitamin B9. Vitamin 
B9 (Folic acid and Folate inclusive) is essential to numerous bodily functions ranging from 
nucleotide synthesis to the remethylation of homocysteine. It is especially important during 
periods of rapid cell division and growth, such as in infancy and pregnancy. Both children and 
adults require folic acid to produce healthy red blood cells and prevent anemia. It is a yellow 
orange crystalline powder that has a molar mass of 441.4 g/mol and melting point of 250°C.  
 
2.8.2 Structure and Functions of Folate Receptors 
The Folate Receptor (FR) is a folate binding protein known as glycosylphosphatidylinositol 
anchored protein, that can actively internalize bound folates and folate conjugated compounds via 
receptor-mediated endocytosis (Kamen 1986; Leamon 1991). It has been found that FR is up-
regulated in more than 90% of non-mucinous ovarian carcinomas. It is also found at high to 
moderate levels in kidney, brain, lung, and breast carcinomas while it occurs at very low levels in 
most normal tissues (Kamen and Smith 2004). The FR density also appears to increase as the 
stage of the cancer increases (Elnakat and Ratnam 2004). It is thus hypothesized that folate 
conjugation to anti-cancer drugs will improve drug selectivity and decrease negative side effects. 
The family of human FR (Mr ~ 38 kDa) consists of three well-characterized isoforms (FR-α, -β, 
and γ) that are ~70–80% identical in amino acid sequence, but distinct in their expression patterns 
(Shen, Ross et al. 1994). FR-α and FR-β are both membrane-associated proteins as a consequence 
of their attachment to a glycosylphosphatidylinositol (GPI) membrane anchor. FR-α, however, 
can be distinguished from FR-β by its higher affinity for the circulating folate coenzyme, (6S)-5-
methyltetrahydrofolate (5- CH3 H4 folate), and by its opposite stereospecificity for reduced folate 
coenzymes (Wang, Shen et al. 1992). FR-α also binds folic acid and physiologic folates with 
77 
 
slightly higher affinity(KD ~ 0.1 nM) (Kamen and Caston 1986) than FR-β (KD ~ 1 nM) (da Costa 
and Rothenberg 1996). FR-γ and a truncated form of the protein, FR-γʹ, lack the GPI anchor and 
are constitutively secreted in barely detectable amounts as soluble forms of the human FR. The 
binding affinity of the secreted FR-γ for folic acid is reportedly to be ~ 0.4 nM (Shen, Wu et al. 
1995). The role of FR in cellular folate transport is not well understood, although a ‘potocytosis’ 
model has been proposed (Anderson, Kamen et al. 1992). FRs were found to be clustered in non-
coated membrane regions called caveolae. Localization of FRs in caveolae and receptor 
internalization can be induced by receptor crosslinking and is regulated by cholesterol (Smart, 
Mineo et al. 1996).  
 
2.8.3 Biological Mechanism 
The FR functions to concentrate exogenous folates and various derivatives into the cell cytosol by 
endocytosis (Kamen 1986). The term endocytosis refers to the process whereby the plasma 
membrane invaginates and eventually forms a distinct intracellular compartment. The endocytic 
vesicles (endosomes) that contain the FR–folate complex rapidly become acidified to ~pH 5 and 
thereby allow the FR to release the folate molecule (Lee, Wang et al. 1996). At this point, 
cytosolic entry of the vitamin can occur by: (1) direct membrane translocation of the protonated 
vitamin species; (2) anion exchange-assisted transport of the vitamin out of the endosome 
(Anderson, Kamen et al. 1992); and (3) simple leakage of the folate during imperfect membrane 
fusion events (Turek, Leamon et al. 1993). It has been known for nearly a decade that simple 
covalent attachment of folic acid to virtually any macromolecule produces a conjugate that can be 





2.8.4 Drug Delivery by Receptor Mediated Endocytosis 
Receptor-mediated endocytosis (RME), also called clathrin-dependent endocytosis, is a process 
by which cells internalize molecules (endocytosis) by the inward budding of plasma membrane 
vesicles containing proteins with receptor sites specific to the molecules being internalized. After 
the binding of a ligand to plasma membrane spanning receptors, a signal is sent through the 
membrane, leading to membrane coating, and formation of a membrane invagination. The 
receptor, its ligand, and anything nearby are then internalized in sub-micrometre sized clathrin-
coated vesicles. Once internalized, the clathrin-coated vesicle uncoats (a pre-requisite for the 
vesicle to fuse with other membranes) and individual vesicles fuse to form the early endosome. 
Since the receptor is internalized with the ligand, the system is saturable and uptake will decline 
until receptors are recycled to the surface.  
 




The prevalence of FR overexpression among human tumors makes it a good marker for targeted 
drug delivery to these tumors. Two strategies have been developed for FR-specific drug targeting: 
(1) coupling to monoclonal antibodies (e.g., MOv18) against the FR; and (2) coupling to folic 
acid, in which folic acid functions as the targeting ligand. High affinity FR binding is retained 
when folate is covalently linked via its g-carboxyl group to a foreign molecule.Among the 
targeting moieties, vitamin folic acid (folate or FOL) has been widely employed as a targeting 
moiety for various anticancer drugs. It is attracted for its high binding affinity, ease of 
modification, small size, stability during storage, and low cost (Lee and Low 1995; Guo, Hinkle 
et al. 1999; Reddy and Low 2000). The high-affinity folate receptor (FR), which is a cell surface-
expressed molecule containing folate binding proteins called GPI (glycosyl phosphatidyl inositol) 
(Lu and Low 2002), is overexpressed in almost all the carcinomas, but has a highly restricted 
distribution of expression in normal cells. For this reason, folic acid has been covalently 
conjugated to anticancer drugs for selective targeting against tumor, which can uptake the drug- 
FOL conjugation by the receptor mediated endocytosis (RME) (Lee and Low 1995). Folate 
targeted drug delivery has emerged as an alternative therapy for the treatment and imaging of 
many cancers and inflammatory diseases. Due to its small molecular size and high binding 
affinity for cell surface folate receptors (FR), folate conjugates have the ability to deliver a variety 
of molecular complexes to pathologic cells without causing harm to normal tissues. Complexes 
that have been successfully delivered to FR expressing cells, to date, include protein toxins, 





CHAPTER 3: SYNTHESIS AND CHARACTERIZATION OF TPGS-DOX-FOL 
CONJUGATE 
3.1 Introduction 
TPGS has been synthesized by conjugating PEG 1000 to α-tocopheryl succinate (TOS) and thus 
TPGS-DOX and TPGS-DOX-FOL conjugates were also synthesized in a similar way. Firstly, the 
terminal hydroxyl group of the TPGS was reacted with succinic anhydride by the ring opening 
polymerization mechanism in the presence of DMAP to form TPGS-SA. Secondly, the carboxyl 
group of the TPGS is activated by NHS using DCC as the catalyst. Now, the amine group of 
DOX interacts with the activated carboxyl group in TPGS-SA to form TPGS-DOX conjugate. 
Thirdly, the NHS ester of folic acid (NHS-FOL), formed by activating folic acid using NHS and 
DCC as catalyst, is allowed to interact with hydrazine hydrate to form Folate-Hydrazide (Guo, 
Hinkle et al. 1999). Finally, the TPGS-DOX conjugate and the Folate-Hydrazide was reacted in 
the presence of acetic acid to form the TPGS-DOX-FOL conjugate. The mechanism for the 
reaction was shown in scheme 3-1, scheme 3-2, scheme 3-3 and scheme 3-4. The synthesized 
conjugates were characterized by Fourier Transform Infrared Spectroscopy (FT-IR) and Nuclear 
Magnetic Resonance (NMR) for the molecular structure. It was further characterized using 




TPGS was purchased from Eastman Chemical Company (TN, USA). Doxorubicin hydrochloride, 
phosphate buffered saline (PBS), N,N’-Dicyclohexylcarbodiimide (DCC), 
Dimethylaminopyridine (DMAP), N-hydroxysuccinimide (NHS), Succinic anhydride (SA), 
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Triethylamine (TEA), diethyl ether, tetrahydrofuran (THF), Hydrazine hydrate and Folic acid 
were obtained from Sigma-Aldrich (St. Louris, MO, USA). All solvents used are HPLC grade, 
which include Dichloromethane (DCM), Acetone and Dimethyl sulfoxide (DMSO) from Sigma-
Aldrich and ethyl acetate from Merck. All reagent water used in the laboratory was preheated 
with Milli-Q Plus System (Millipore Corporation, Bredford, USA). 
 
3.3 Methods 
The TPGS-DOX and the TPGS-DOX-FOL conjugates were synthesized and characterized by the 
methods described below. 
 
3.3.1 Synthesis of TPGS-DOX  
3.3.1.1 Succinoylation of TPGS 
Succinoylated TPGS was synthesized by the ring-opening polymerization mechanism in the 
presence of DMAP where the hydroxyl group of TPGS reacts with Succinic anhydride. In brief, 
TPGS (0.77 g), succinic anhydride (0.10 g) and DMAP (0.12 g) were mixed and allowed to react 
at 100° C under nitrogen atmosphere for 24 hrs (Cao and Feng 2008). The mixture was cooled to 
room temperature and taken up in 5.0 mL cold DCM. It is then filtered to remove excessive 
succinic anhydride and precipitated in 100 mL diethyl ether at -10°C overnight. The white 
precipitate was filtered and dried in vacuum to obtain succinoylated TPGS. However, complete 
succinoylation is necessary to avoid the polymer cross-linking during the Doxorubicin 





































































Scheme 3-1 Scheme of TPGS-DOX Conjugation 
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The succinoylated TPGS (191.3 mg) was reacted with DOX.HCl (102.5 mg) in the presence of 
DCC (74.2 mg), NHS (41.4 mg) and TEA (50 μL) in DMSO at room temperature under nitrogen 
atmosphere for 24 hrs. The obtained product was filtered to remove N,N-dicyclohexylurea (DCU) 
and then dialyzed using MWCO 1,000 membrane in DMSO for 24 hrs to remove excess reagents 
and the unconjugated DOX. It was further dialyzed against Millipore water for 24 hrs to remove 
DMSO. The resultant solution was freeze-dried to get the red powder of TPGS-DOX conjugate. 
The conjugate scheme is shown in Scheme 3-1. 
 
3.3.2 Synthesis of TPGS-DOX-FOL 
3.3.2.1 Folate-Hydrazide Synthesis 
As to interact with hydrazine hydrate, NHS ester of folate (FOL) is required. Three grams of folic 
acid were dissolved in 60 mL DMSO. 1.1- molar excess of NHS and DCC were then added and 
reacted for 24 hrs at room temperature under stirring and N2 atmosphere, shielded from light. The 
by-product DCU was then removed by filtration and the DMSO solution of NHS-FOL was stored 
at -20° C until use. In the synthesis of folate-hydrazide, 60 mL of the above NHS-folate solution 
were added to 1.7 mL hydrazine hydrate with constant stirring at room temperature under 
nitrogen atmosphere for about 6 hrs. The product folate-hydrazide was converted to a 
hydrochloride salt with the addition of 17 mL 0.5 N HCl and then precipitated with four volumes 
of acetonitrile/dithylether (1:1) overnight. The precipitate was pelleted by centrifugation, 
redissolved in a small volume of water and then reprecipitaed with 10 volumes of ethanol in 
freezer overnight. The pellet was then washed sequentially using ethanol and diethylether and 

















































Scheme 3-2 Scheme of FOL-Hydrazide formation 
 
 
3.3.2.2 TPGS-DOX-FOL Conjugation 
The TPGS-DOX-FOL conjugate synthesis involves the following steps. The TPGS-DOX 
conjugate (230 mg, 0.10 mmol) and FOL-hydrazide (220 mg, 0.46 mmol) were dissolved in 
anhydrous DMSO (20 mL), and AcOH (30 μL, 0.48 mmol). The reaction was performed for 24 
hrs with stirring in the dark under nitrogen atmosphere at room temperature. Then, the mixture 
was filtered and dialyzed against DMSO for 24 hrs, followed by DI water for 48 hrs. The product 





































































         







3.3.3 Characterization of TPGS-DOX and TPGS-DOX-FOL Conjugates 
3.3.3.1 FT-IR 
The chemical structure of TPGS-DOX and TPGS-DOX-FOL were studied by the Fourier 
Transform Infrared Spectroscopy (FT-IR) (Shimadzu, Japan). For the sample preparation, we 
used 99% KBr with 1% TPGS-DOX or TPGS-DOX-FOL conjugate and mix them. The mixture 
is then pressed using high pressure into a transparent tablet. 
 
3.3.3.2 ¹H-NMR 
The molecular structure of TPGS-DOX, FOL-NH-NH2 and TPGS-DOX-FOL were confirmed by 
¹H-Nuclear Magnetic Resonance (NMR) in DMSO-d6 graded solvent at 300MHz (Bruker 
ACF300, Germany). 
 
3.3.3.3 Drug Conjugation Efficiency 
The amount of DOX conjugated to TPGS in the TPGS-DOX conjugate and in the TPGS-DOX-
FOL conjugate were measured individually using a microplate reader (GENios, Tean, 
Switzerland) in DMSO with fluorescence detection at Excitaion wavelength, λex = 480 nm and 
Emission wavelength, λem = 560 nm. A standard curve was obtained using pristine DOX at a 






3.4 Results and Discussion 
3.4.1 FT-IR Spectra 
Fig 3-1 shows the FT-IR spectra of FOL, TPGS-DOX and TPGS-DOX-FOL, from which we can 
see that the 3000-1500 1/cm region is known as the functional group region of FOL and the other 
important region, 900-700 1/cm region, is characteristic of the bending of the functional groups 
(Cummings and McArdle 1986). The absorption in 2960-2820 1/cm region stands for the C-H 
stretches both symmetric as well as asymmetric. The region of 1720-1560 1/cm showed the 
presence of C=O group. The region of 3600-3300 1/cm corresponds to -OH, -NH- and NH2 
group. From the spectrum of TPGSDOX conjugate, we can find that the broad band in 3500-3300 
1/cm attributed to the overlapping of O-H and N-H stretching frequency. The peak at 1450 1/cm 
indicated the N-H deformation in secondary amine structure, which was attributed to the linkage 
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In the spectrum of TPGS-DOX-FOL, the region of 3500-3300 cm-1 was reduced. The peaks in 
1720-1560 cm-1 was shifted to 1620-1460 due to the presence of C=N by the interaction between 
DOX and FOL, revealing the successful conjugate of TPGS-DOX and FOL. 
 
3.4.2 ¹H-NMR Spectra 
The typical ¹H NMR spectra of TPGS-DOX, FOL, FOL-NH-NH2 and TPGS-DOX-FOL are 
shown in Fig 3-2a, 3-2b, 3-2c and 3-2d respectively. The spectrum of TPGS-DOX (Fig 3-2a) 
contained signals from DOX and TPGS exhibiting typical peaks of DOX between 5-6 ppm, 
which are characteristic of phenolic protons of DOX, and peaks of TPGS at 3.6 ppm, which is the 
characteristic of methylene protons of poly ethylene oxide (PEO) part in TPGS. The peak at 
around 8 ppm is characteristic of amide protons, which indicates that the DOX has been 
conjugated with the TPGS by forming an amide bond. The spectrum of FOL (Fig 3-2b) exhibited 
typical peaks of FOL at 1.85-2.10 ppm (β-CH2 of glutamic acid), 2.30 ppm (γ-CH2 of glutamic 
acid), 6.62 and 7.61 ppm (aromatic protons), 8.1 ppm (aliphatic amide proton) and 8.6 ppm 
(pteridine proton). The peak at 11.4 ppm is also characteristic of carboxylic groups. The spectrum 
of FOL-NH-NH2 (Fig 3-2c) was similar to that of FOL. However, the exhibited peak at 8.1 ppm 
has split into multiple peaks from one sharp peak. This suggested the presence of additional 
amide groups. The peak at 11.4 ppm has been replaced by a smaller peak at around 11 ppm, 
which indicated that one of the carboxylic groups of FOL has reacted. The spectrum of TPGS-
DOX-FOL (Fig 3-2d) retained the characteristic large peak of TPGS-DOX at 3.6 ppm and the 
characteristic peaks of FOL- NH-NH2 from 6-9 ppm are also present. This confirmed the 
conjugation of TPGS-DOX-FOL. In addition, the peak at 11.4 ppm suggested the presence of 
carboxylic group, which further implies successful conjugation, as this group is originally present 





Fig 3-2  ¹H-NMR spectra of (a) TPGS-DOX with the insert for a higher magnification of the 
region between 6 and 14 ppm, (b) FOL with the insert for a magnification of the region between 8 
and 11 ppm and 3 and 4 ppm, (c) FOL-NH-NH2, (d) TPGS-DOX-FOL 
 
 
3.4.3 Drug Loading Efficiency 
The DOX content in the TPGS-DOX conjugate was determined using the microplate reader with 
fluorescence detection at 480 nm and was found to be 6.0 wt% and the DOX content in TPGS-
DOX-FOL conjugate was determined to be 13.0 wt%. This drug loading capacity of the TPGS-
DOX conjugate seems comparable to other polymer-DOX conjugates such as PEG-DOX 
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conjugates, which has a drug loading of 2.7 – 8.0 wt% varying due to branching of polymer and 
the nature of the linker (Veronese, Schiavon et al. 2005), HPMA copolymer-DOX conjugate 
which has a drug loading of 8.5 wt% (Vasey, Kaye et al. 1999), another PEG-DOX conjugate 
with 2.5-5 wt% drug loading (Rodrigues, Beyer et al. 1999) and PGA-DOX conjugate having a 
drug loading of 5-16% ( Hoes, C. J. T., J. Grootoonk, et al. 1993). It is also found to be better 
than the other polymer-drug conjugates like PEG-Gemcitabine conjugate, wherein the 
Gemcitabine drug is loaded at 0.98-1.95 wt% (Pasut, Canal et al. 2008). This facilitates the 
possibility for the conjugate to go through the clinical trials. Now, the drug loading capacity of 
TPGS-DOX-FOL conjugate is also found to be a better value comparing other polymer-drug 
conjugates like FOL-PEG-Gemcitabine which has a drug loading of 2.11 wt% (Pasut, Canal et al. 
2008) and can be further improved by altering parameters like the type of branching and using a 
linker or a spacer. 
  
3.4.4 Conclusions 
The TPGS-DOX-FOL conjugate was synthesized via the reaction between the TPGS-DOX, 
which is prepared by the interaction of the succinoylated TPGS and amine group of DOX, and 
FOL-NH-NH2, which is formed by the interaction of NHS ester of folate and hydrazine hydrate. 
The conjugates TPGS-DOX and TPGS-DOX-FOL were characterized by FT-IR and ¹H-NMR to 
study the molecular structure and to confirm the conjugation. This shows successful synthesis of 
the conjugates. The drug loading in case of both the TPGS-DOX and the TPGS-DOX-FOL 




CHAPTER 4: IN VITRO STUDIES ON DRUG RELEASE KINETICS, 
CELLULAR UPTAKE AND CELL CYTOTOXICITY OF TPGS-DOX AND 
TPGS-DOX-FOL CONJUGATES 
4.1 Introduction 
The drug release from the conjugate is an important factor to be considered for its therapeutic 
efficiency. Knowing that mostly, the drug release is mediated by simple hydrolysis, we have 
studied the release kinetics of the drug at 37°C with different pH values. Also, the cellular uptake 
of the conjugates has been studied by calculating the percentage uptake of the conjugate in vitro 
using the breast cancer cells, MCF-7. The cellular uptake of the conjugates are then visualized by 
Confocal Laser Scanning Microscopy (CLSM). TPGS is said to enhance the cellular uptake in the 
human intestinal Caco-2 cell line (Traber, Thellman et al. 1988) and in the human colon 
carcinoma cells (Win and Feng 2006) by inhibiting the action of P-glycoprotein. Further, it was 
demonstrated that the folate can target the cancer cells and increase the cellular uptake of the 
conjugates (Zhang, Xiang et al. 2006; Zhang, Huey Lee et al. 2007). The in vitro cell viability 
study was done using CCK-8 assay in MCF-7 breast cancer cells. All the experiments were done 
for the TPGS-DOX-FOL conjugate in comparison with the conjugate TPGS-DOX and the 
pristine DOX. 
 
4.2 Materials and Methods 
4.2.1 Materials 
Phosphate buffered saline (PBS), Dulbecco’s Modified Eagel Medium (DMEM), penicillin-
streptomycin solution, Trypsin-EDTA, Triton-X 100 and Tris buffer were obtained from Sigma-
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Aldrich (St. Louris, MO, USA). Cell Counting Kit – 8 (CCK-8) was obtained from Dojindo 
Laboratories, Tokyo. Fetal bovine serum (FBS) and RPMI medium without folate were received 
from Gibco (Life Technologies, AG, Switzerland). 
 
4.2.2 In vitro Drug Release 
In vitro DOX release from the conjugate was performed in triplicates in 1X PBS at pH 3.0, 5.0 
and 7.0 at 37°C, respectively. The solution of the conjugates TPGS-DOX and TPGS-DOX-FOL 
of 200 μg/mL equivalent DOX concentrations was placed in a dialysis bag (MW cutoff 1,000) 
and incubated in 20 mL of the PBS solution with gentle shaking in the water bath shaker. The 
PBS solution outside the dialysis solution was collected at designated time intervals and equal 
volume of fresh medium was compensated. The released DOX was determined by fluorescence 
detection at 480 nm using the microplate reader (GENios, Tecan) with the excitation wavelength 
at 480 nm and the emission wavelength at 580 nm with the help of a calibration curve of DOX in 
PBS, range from 0 to 1 μg/mL with R²=0.9992. 
 
4.2.3 Cell Culture 
MCF-7 breast adenocarcinoma cells (American Type Culture Collection, VA) were used as the in 
vitro model to study the cellular uptake and the cell viability. The cells were cultured in the RPMI 
1640 medium without folate or DMEM, both supplemented with 10% PBS, 1% penicillin-
streptomycin solution, and incubated in SANYO CO2 incubator at 37°C in humidified 
environment of 5% CO2. The medium was replenished every day until confluence was achieved. 





4.2.4 In vitro Cellular Uptake 
MCF-7 breast adenocarcinoma cells were seeded in 96-well black plates (Costar, IL, USA) at a 
density of 3x105cells/well. After the cells reached about 70-80% confluence, they were incubated 
with 100μL of TPGS-DOX-FOL or TPGS-DOX or free DOX solution in medium at 1 μg/mL 
drug concentration for 0.5, 1.5, 4, 6 hrs, respectively. For each sample, we seeded six wells for 
positive control and six wells for sample wells. At the designated time interval, the sample wells 
were washed three times with 50 μL cold PBS and then added 100 μL culture medium. After that, 
all the cells were lysed by 50 μL 0.5% Triton in 0.2M NaOH. The fluorescence intensity of each 
sample was detected by the microplate reader (Tecan, Mannedorf, Switzerland, λex = 480 nm, λem 
= 580 nm) calibrated with standard solutions of DOX in similar condition. Cellular uptake 
efficiency was expressed as the percentage of the fluorescence associated with the cell vs. that 
presented in the positive control (Mo and Lim 2005). 
 
4.2.5 Confocal Laser Scanning Microscopy (CLSM) 
MCF-7 breast adenocarcinoma cells were incubated with TPGS-DOX-FOL conjugate or TPGS-
DOX conjugate or free DOX medium solution at 1 μg/mL DOX concentration at 37°C for 4 hrs. 
The cells were then rinsed with cold PBS three times, fixed by 75% ethanol for 20 mins, and then 
washed twice by PBS. The cells were finally mounted by the mounting medium (DAKO® 
Fluorescent Mounting Medium) and observed under confocal laser scanning microscopy (Zeiss 
LSM 510, Germany). Fluorescein Isothiocyanate (FITC) dye was conjugated to TPGS in the 
presence of DCC (Kolhe, Khandare et al. 2004) to observe the TPGS uptake in the cells. The 
fluorescence was observed at λex = 495 nm, λem = 520 nm. The uptake of pristine DOX, TPGS-
DOX, TPGS-DOX-FOL was observed at λex = 480 nm, λem = 580 nm. Also, folic acid uptake by 
the cells was observed at λex = 543 nm, λem = 590 nm. 
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4.2.6 In vitro Cytotoxicity 
In vitro cytotoxicity study of free DOX, TPGS-DOX and TPGS-DOX-FOL conjugates were 
quantitatively measured by employing on MCF-7 breast adenocarcinoma cells. MCF-7 cells were 
cultivated in RPMI 1640 medium without folate, supplemented with 10% FBS and 1% antibiotics 
at 37°C in humidified environment of 5% carbon dioxide. The cells were seeded at a density of 
5x10³ cells/well in 96-well plates (Costar, IL, USA) incubated for 24 hrs and the medium was 
then replaced by the free DOX , TPGS-DOX conjugate or TPGS-DOX-FOL conjugate 
respectively at various equivalent drug concentrations from 0.002 to 100 μM in the medium. The 
cell viability was determined by the CCK-8 assay. At the designated time intervals 24, 48, 72 hrs, 
the medium was removed and the wells were washed twice with PBS. 100μl of the CCK-8 
solution is added to each well of the plate and incubated for about 3 hrs in the incubator. Each 
well was analyzed by the microplate reader with absorbance detection at 570 nm. The cell 
viability was calculated using the formula, 
                             Cell viability (%) = (Abss / Absc) x 100 
Where Abss is the fluorescent absorbance of the wells containing the drug samples and Absc is the 
fluorescent absorbance of the wells containing the culture medium used as a positive control. 
 
4.2.7 Statistics 
Statistical analysis was conducted by using the Student’s t-test with a significance of p<0.05. 
 
4.3 Results and Discussion 
4.3.1 In vitro Drug Release 
Fig 4-1 shows the in vitro release profiles of DOX from the conjugates TPGS-DOX and TPGS-
DOX-FOL at various pH conditions such as 3.0, 5.0 and 7.0. It can be seen that the release of 
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DOX from the conjugates was in a slow and sustained manner, which is pH dependent and 
increases as the pH decreases. The cumulative release of the drug from TPGS-DOX-FOL and 
TPGS-DOX at pH 3.0 for the first 15 days was found to be 30.23±2.16% and 98.34±1.1% 
respectively. This is understandable. For TPGS-DOX, the TPGS and DOX are linked through the 
degradable amide bond that can be broken easily under acidic conditions by hydrolysis. Also 
DOX was stable under the pH range <6.5. Since the proton concentration inside the lysosomes is 
higher than that outside the cells, gradual hydrolysis occurs inside the cells at lower pH which 
help in the degradation of the bond to release the DOX. For TPGS-DOX-FOL, instead, there is an 
additional bond, which has to be broken for the DOX to get released, which makes the release 
relatively slower than that from the TPGS-DOX. At pH 5.0, the release percentage of DOX from 
TPGS-DOX and TPGS-DOX-FOL after 15 days was found to be 53.26±3.6% and 5.24±0.78% 
respectively and at pH 7.0, it is 39.2±2.15% and 3.87±1.61% respectively. The release profile 
confirmed that the linkage is stable under alkaline conditions (pH >7) outside the cell and 
degraded in acidic conditions which attributes positive effects of the prodrug strategy. It should 
be pointed out that such a pH dependent drug release feature has advantages for cancer treatment, 
which is equivalent a passive targeting effect since tumor has been found in an acidic condition in 
the body. 
 The pharmacological activity of macromolecular prodrug requires the release of drugs 
from the conjugate by chemical or enzymatic reactions and this plays an important role in cancer 
chemotherapy. In terms of drug release, the stability of the linkage between the carrier and the 
drug and the site of regeneration of the free drug from the conjugate are important factors. In 
most cases, the anticancer drug is released from the polymer carrier through simple hydrolysis 
(Takakura and Hashida 1995). The free DOX is known to be stable in the pH range 3.0-6.5 
(Vigeveni, A. and M. J. Williamson. “Doxorubicin”. New York, Academic Press. 1980). A well-
known concept for the mechanism of action of macromolecular prodrugs is the principle of 
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‘lysosomotropic’ delivery which was advocated more than two decades ago by Trouet et al. 
(Trouet A 1972). Thus the release profile confirmed that the biodegradable bonds between the 
drug and the carrier are stable under alkaline conditions and that are broken under acidic 
conditions in the lysosomes.       
 
                        
 
 
Fig 4-1 In vitro release of DOX from TPGS-DOX and TPGS-DOX-FOL conjugates incubated in 




4.3.2 In vitro Cellular Uptake 
The targeting effect of the TPGS-DOX-FOL conjugate was evaluated by investigating the cellular 
uptake of the free DOX, and the conjugates of TPGS-DOX and TPGS-DOX-FOL by using the 
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MCF-7 breast cancer cells as an in vitro model. Fig 4-2 shows the cellular uptake efficiency of 
the DOX, TPGS-DOX and TPGS-DOX-FOL after 0.5, 1.5, 4 and 6 h incubation with MCF cells 
at 1 μg/mL DOX equivalent concentration at 37°C. It can be seen from the figure that after 0.5 
hour culture, the cellular uptake of DOX, TPGS-DOX and TPGS-DOX-FOL is 70.2, 80.9 and 
86.0% respectively, which shows 15.2% increase by TPGS conjugation and further 6.3% increase 
by targeting effect of FOL. After 1.5 hour culture, the cellular uptake of DOX, TPGS-DOX and 
TPGS-DOX-FOL is 77.4, 81.3 and 87.0% respectively, which shows 5.04% increase by TPGS 
conjugation and further 7.01% increase by targeting effect of FOL. After 4 hour culture, the 
cellular uptake of DOX, TPGS-DOX and TPGS-DOX-FOL is 79.2, 84.2 and 92.8% respectively, 
which shows 6.31% increase by TPGS conjugation and further 10.2% increase by targeting effect 
of FOL. After 6 hour culture, the cellular uptake of DOX, TPGS-DOX and TPGS-DOX-FOL is 
83.1, 87.0 and 95.5% respectively, which shows 4.69% increase by TPGS conjugation and further 
9.77% increase by targeting effect of FOL. It can thus be concluded that (1) the benefits in 
cellular uptake of DOX by TPGS conjugation and by TPGS+FOL conjugation are significant at 
the level of 5-10% increase and (2) incubation time is also an important factor. It seems that the 
benefit due to TPGS conjugation decreases with time while the targeting effect due to 
TPGS+FOL conjugation increases with time, both of them becoming saturated with time.  
The cell uptake differences between the free drug DOX and the conjugates TPGS-DOX-FOL and 
TPGS-DOX, is mainly due to the Multi-Drug Resistance (MDR) effect, that is caused by the over 
expression of transporter proteins such as P-glycoproteins which is an energy dependent drug 
efflux to reduce the intracellular drug levels. These transporters are capable of pumping out many 
anticancer drugs that diffuse into the plasma membrane. For the DOX, it is said that most of the 
drug would be effluxed out by P-glycoproteins except those bound to DNA after entering the 
cells (Zhang and Feng 2006). The TPGS is said to inhibit the action of P-glycoproteins and only 
less drug will efflux out from the cells attributing to higher uptake efficiency (Dintaman and 
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Silverman 1999). In the case of TPGS-DOX-FOL conjugate, further the uptake is mediated by the 
targeting effect of folate. It is evident that the P-gp efflux affected the uptake of free doxorubicin 
compared to the uptake of folate-targeted liposomal doxorubicin in a MDR cell line (Goren, 
Horowitz et al. 2000).  
                          
 
 
Fig 4-2 Cell uptake efficiency incubated with pristine DOX, TPGS-DOX or TPGS-DOX-FOL 
conjugate for 0.5, 1, 4, 6 h respectively at an equivalent DOX concentration of 1µg/mL in MCF-7 
breast cancer cells (Mean±SD and n=6). 
 
 
4.3.3 Confocal Laser Scanning Microscopy (CLSM) 
The cellular uptake of TPGS, DOX, FOL, TPGS-DOX-FOL and TPGS-DOX conjugates by the 
MCF-7 breast adenocarcinoma cells were further visualized by confocal laser scanning 
microscopy (CLSM) and their images are shown in Fig 4-3. The five pictures in the figure show 
the confocal images of MCF-7 cancer cells after 4 h incubation with (a) TPGS-FITC, (b) DOX, 
99 
 
(c) FOL, (d) TPGS-DOX and (e)TPGS-DOX-FOL at the concentration of 1μg/mL TPGS, FOL 
and equivalent DOX concentration, respectively. Fig 4-3 (5a) shows the FITC fluorescence at λex 
= 495 nm, λem = 520 nm, from which the TPGS was found distributed in the cytosol than the 
nucleus. This is because TPGS is an inhibitor of P-gp, which also improves the membrane 
interactions (Youk, Lee et al. 2005). Fig 4-3 (5b), Fig 4-3 (5d) and Fig 4-3 (5e) show the DOX 
fluorescence observed from the DOX, TPGS-DOX and TPGS-DOX-FOL respectively at λex = 
480 nm, λem = 580 nm. It can be seen from Fig 4-3 (5b) that DOX was found mainly present 
within the nucleus. The fluorescence in the cells is generally weak, which indicates a low DOX 
accumulation. This is due to the MDR effect caused by the P-glycoproteins, where most of the 
free DOX would be effluxed out of the cells and only the drug that binds to the DNA in the 
nucleus will remain inside the cell (Zhang and Feng 2006). Fig 4-3 (5c) shows the fluorescence 
from FOL, which was observed at λex = 543 nm, λem = 590 nm. From this figure, the intense red 
fluorescence was observed around the nucleus and a broad distribution of fluorescence in the 
cytosol was also found. This suggests that the folic acid is endocytosed through the folate 
receptor-mediated mechanism, by attaching to the over expressed folate receptors found on the 
surface of the cancer cells (Lu and Low 2002). From Fig 4-3 (5d) for the TPGS-DOX, it can be 
found that the fluorescence is distributed more in the cytoplasm than in the nucleus, which shows 
a greater cellular uptake compared to the DOX. This is an indication that TPGS-DOX is able to 
avoid efflux by P-gp. Although the fluorescence is found mostly in the cytoplasm, which suggests 
that most of the DOX is still in conjugate form, the fluorescence in the nuclei indicates that some 
DOX has already been released by hydrolysis and intercalated with DNA. This result is similar to 
that obtained from the PAMAM-hyd-DOX conjugates which showed that the conjugate is able to 
release functional DOX (Lai, Lou et al. 2007). Fig 4-3 (5e) shows that in comparison to DOX and 
TPGS-DOX, the TPGS-DOX-FOL conjugate exhibited significantly greater cellular uptake with 
a broad intracellular distribution around the nucleus and the fluorescence appears to be distributed 
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more in the cytosol than in the nucleus. The intense fluorescence is generally due to the targeting 
effects of the FOL via receptor mediated endocytosis mechanism (Yoo and Park 2004). Lesser 
fluorescence in the nucleus was mainly due to slower release of the DOX from the conjugate. 
 
 
Fig 4-3 Confocal laser scanning microscopy (CLSM) of MCF-7 cells after 4 h incubation with (a) 
TPGS-FITC, (b) pristine drug DOX, (c) FOL, (d) TPGS-DOX conjugate and (e) TPGS-DOX-
FOL conjugate at an equivalent DOX concentration of 1µg/mL 
 
 
4.3.4 In vitro Cytotoxicity 
The breast cancer cell line MCF-7 was used as an in vitro model to evaluate the cell cytotoxicity 
of the free DOX and the conjugates TPGS-DOX and TPGS-DOX-FOL. Fig 4-4 shows the 
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cellular viability of MCF-7 cells after (a) 24, (b) 48, (c) 72 hour culture at 37ºC with the DOX, 
TPGS-DOX and TPGS-DOX-FOL at the various equivalent DOX concentration of 0.002, 0.02, 
0.2, 2, 20 and 100 μM respectively. The cellular viability was determined by the CCK-8 assay. 
The mortality is difference of the viability from 100%. It can be concluded from these three 
figures that (1) the benefits in resulting higher cytotoxicity by TPGS conjugation and by targeting 
effect of FOL are both significant and (2) the benefits are also dependent on the DOX 
concentration. For example, After 24 hour cell culture at 0.002 μM equivalent DOX 
concentration, the mortality of the MCF-7 cells were 9.36, 30.4 and 37.6% for the DOX, TPGS-
DOX and TPGS-DOX-FOL, respectively, which shows 225% increase by TPGS conjugation and 








Fig 4-4 Cell viability of MCF-7 breast cancer cells after incubation with the TPGS-DOX 
conjugate and TPGS-DOX-FOL conjugate in comparison with that of the pristine DOX after (a) 




After 24 hour cell culture at 100 μM equivalent DOX concentration, however, the mortality of the 





respectively, which shows 23.2% increase by TPGS conjugation and further 31.0% increase by 
targeting effect of FOL. A similar conclusion can be reached from the results obtained after 48 or 
72 hour cell culture.  
Alternatively, the in vitro cytotoxicity of a drug can be quantitatively evaluated by IC50, which is 
defined as the drug concentration needed to kill 50% of the cancer cells cultured with the drug in 
a designated time period, for example, in 24 hours etc. Table 4-1 lists the IC50 values of DOX in 
the form of the free drug, the TPGS-DOX and the TPGS-DOX-FOL conjugate after 24, 48, 72 h 
cell culture at 37°C respectively. It can be seen from this table that after 24 hour cell culture, the 
IC50 is 27.9 μM for the free DOX, 22.8 μM for TPGS-DOX and 0.590 μM for TPGSDOX- FOL, 
which implies that TPGS-DOX conjugate could be 22.4 % more effective than DOX and TPGS-
DOXFOL could be 97.4% more effective than TPGS-DOX or 97.9% more effective than the 
DOX. The results after 48 and 72 hour cell culture showed the same significant enhancement of 
the TPGS-DOX and TPGS-DOX-FOL conjugates. 
 
 
Table 4-1 IC50 values (in equivalent µM DOX level) of MCF-7 cancer cells cultured with the 
TPGS-DOX-FOL conjugate, TPGS-DOX conjugate and the pristine DOX in 24, 48 and 72 hrs 
 
                                       IC50  (µM) 
Incubation time (hr) DOX TPGS-DOX TPGS-DOX-FOL
24 27.1 22.8 0.590 
48 0.620 0.1022 0.0641 






Although, usually lower in vitro cytotoxicity is known for polymeric doxorubicin compounds 
such as hydroxypropylmethacrylate-copolymer conjugates (Duncan 1999; Kopecek, Kopeckova 
et al. 2000), doxorubicin-cephalosporin prodrugs (Veinberg, Shestakova et al. 2004), in this case, 
the TPGS-DOX conjugation results in lower IC50 values in vitro than the parent drug which might 
be due to the conjugation of the DOX with TPGS, that acts as an inhibitor of P-glycoprotein that 
is said to lower the MDR effect by decreased efflux of the drug (Dintaman and Silverman 1999). 
TPGS also has enhanced permeability due to the inhibition of P-glycoprotein. Also, TPGS 
possess great ROS (reactive oxygen species) generating ability (Youk, Lee et al. 2005) which 
enables it to facilitate increased cytotoxicity. Thus the TPGS-DOX is said to have a much lower 
IC50 values which can increase the therapeutic effect of the drug. Now, TPGS-DOX-FOL has 
much lower IC50 value than both the TPGS-DOX conjugate and the parent drug. This might be 
due to the targeting effect of the FOL, which enables increased amount of drug to enter the cancer 
cells and lesser amount of drug to enter the normal cells. It was also shown that the folate 
receptor-targeted formulation has lower IC50 value than the non-targeted formulations (Lu, Wu et 
al. 2007; Zhang, Huey Lee et al. 2007), which is similar in our case.  
 
4.4 Conclusions 
In vitro release of DOX from the conjugates, TPGS-DOX and TPGS-DOX-FOL, were found to 
be pH dependent, where the TPGS-DOX-FOL releases the drug in a slow and sustained manner 
that the TPGS-DOX, whose release is slower than the pristine DOX. TPGS-DOX-FOL 
conjugates gave higher cellular uptake efficiency that the TPGS-DOX conjugate and free DOX at 
all incubation times, which confirms the targeting effect of folate. The in vitro confocal laser 
scanning microscopy imaging showed that the TPGS-DOX-FOL conjugate was found distributed 
in the cytoplasm of MCF-7 cells, confirming the increased uptake by the cell. Also, the CLSM 
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images of TPGS and FOL showed that TPGS can inhibit P-glycoproteins, which resulted in its 
accumulation inside the cell and FOL can enter the cells by targeting. TPGS-DOX-FOL 
conjugate showed higher in vitro cytotoxicity in MCF-7 cells and achieved much lower IC50 
values in comparison with TPGS-DOX and pristine DOX. As the time increases, the cytotoxicity 
also increases for TPGS-DOX-FOL conjugate. However, in vivo studies are required to confirm 















CHAPTER 5: IN VIVO STUDIES ON PHARMACOKINETICS AND 
BIODISTRIBUTION OF THE TPGS-DOX-FOL CONJUGATE 
 
5.1 Introduction 
The in vivo pharmacokinetics (PK) and the in vivo biodistribution (BD) of the conjugates TPGS-
DOX-FOL, TPGS-DOX and DOX were investigated in male SD rats and compared. The in vivo 
pharmacokinetics makes use of the non-compartmental model for analysis of the therapeutic 
effects of the conjugates. In the case of in vivo biodistribution, HPLC was used to detect the drug 
amount in the tissues, which is easy to handle with acceptable sensitivity and selectivity. Other 
few methods have also been developed for detecting the amount of drug in blood and tissues. The 
blood and the organs are collected from the rats after administration and is undergone liquid-
liquid extraction after which the samples were detected using HPLC with fluorescence detection. 
 
5.2 Materials and Methods 
5.2.1 Animal Type 
Male Sprague-Dawley (SD) rats weighing 150-200 g and 4-5 weeks old were provided by the 
Laboratory Animals Centre of Singapore and maintained at the Animal Holding Unit (AHU) of 
National University of Singapore. They were kept in well-ventilated rooms at a temperature of 
25°C and a humidity of 50-60% under nature lighting conditions. All caring and handling 
procedures for rats and experimental protocols were approved by Institutional Animal Care and 
Use Committee (IACUC), Office of Life Sciences, National University of Singapore under the 




Fig 5-1 Experimental SD rats, who had sacrificed their lives for the well being of human 
 
5.2.2 In vivo Pharmacokinetics 
5.2.2.1 Drug Administration and Blood Collection 
The rats were randomly assigned to three groups, each of four rats. One group is for the i.v. 
administration of free DOX, one group for TPGS-DOX conjugate and the other for TPGS-DOX-
FOL conjugate. The free DOX and both the conjugates, TPGS-DOX and TPGS-DOX-FOL, were 
diluted in normal saline containing 1.9% w/v NaCl to obtain the required injection volume of 1-
1.5 mL. Intravenous injection was given via the tail vein at a 5mg/kg equivalent drug dosage. All 
the rats were observed for mortality, general condition and potential clinical signs. The blood 
samples were collected in heparinized tube at 0, 10, 30 min, 1, 2, 4, 8, 12, 24, 48, 72 h after the 
administration of the DOX and the conjugates.  
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5.2.2.2 Sample Analysis 
Plasma samples were harvested by centrifugation at 1500xg for 10 mins and stored at -20°C until 
analysis. Liquid-liquid extraction was performed prior to the HPLC analysis. Briefly, the plasma 
(100 μL) was mixed with 100 μL of 10 mM phosphate-buffered saline (pH 7.8). The drug was 
extracted by dichloromethane-isopropanol (4:1, v/v) on a vortex-mixer for 1 min. Upon 
centrifugation at 2000xg for 15 mins, the upper aqueous layer was removed by aspiration and the 
organic layer was transferred to a glass tube and evaporated under nitrogen at room temperature 
overnight. The residue was then dissolved in 100 μL of the HPLC mobile phase (1/15 M 
KH2PO4/CH3CN=75:25 v/v, pH 4.16 adjusted with H3PO4) by vortex and transferred to auto 
sampler vials containing limited-volume inserts (100 μL). The standards were prepared using 
blank plasma with a series of concentration of commercial DOX (0.025 μg/mL – 10 μg/mL) 
followed by the same procedure as the blood samples were treated. The drug concentrations in 
samples were calculated using a standard calibration curve. For the HPLC analysis, the drug 
concentration in plasma was determined using Agilent 110 Series installed with Agilent Eclipse 
XDB-C18 column with 5 μm pore size. The mobile phase was delivered at a rate of 1 mL/min. 20 
μL of the sample were injected into the instrument and the column effluent was detected with a 
fluorescent detector (λex = 470 nm, λem = 585 nm) (Watson, Stewart et al. 1985). 
 
5.2.2.3 Pharmacokinetic Parameters 
Non-compartmental Analysis (NCA), done by Kinetica Software (Thermo Electron Corporation, 
USA), provides an estimate of the kinetic parameters of a drug based on statistical moment 
theory. As for the specific parameters, the maximum drug concentration (Cmax) and the 
corresponding time (tmax) can be observed from the plasma concentration vs time curve. The 
109 
 
elimination half-life (t1/2), an important index, can be calculated as㏑2/λn, in which λn
 
is the 
elimination constant obtained via log-linear regression analysis of the terminal phase of the 
profile. The area under the curve (AUC) and area under the first moment (AUMC) can be figured 
out using log-linear trapezoid rule. The mean residence time (MRT) is calculated as 
AUMC/AUC. Apparent volume of distribution at steady state (Vss) and plasma clearance (CL) 
were obtained as Dosage × AUMCinf/(AUCinf)
2 





mean the corresponding value from 0 to infinity. 
 
5.2.3 In vivo Biodistribution 
5.2.3.1 Drug Administration and Tissue Collection 
The SD rats were randomly assigned to three groups, i.e. Group A with i.v. injection of the 
pristine DOX suspension, Group B of the TPGS-DOX conjugate and Group C of the TPGS-
DOX-FOL conjugate at the equivalent 5 mg/kg, respectively. Each group has 4 sets 
corresponding to 4 time points, and each set with 3 rats. Before drug administration, commercial 
DOX or TPGS-DOX conjugate were diluted in normal saline containing 1.9% w/v NaCl to obtain 
an estimated injection volume of 1-1.5 ml. Intravenous injection was given via the tail vein at a 5 
mg/kg equivalent drug dosage. All animals were observed for mortality, general condition and 
potential clinical signs. Animals in each set were sacrificed by cardiac stick exsanguinations at 
0.5, 2, 8 and 24 h respectively after the injection and tissues (heart, spleen, stomach, lung, 
intestine, kidney and liver) were collected. The tissues were then washed with saline and stored at 
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5.2.3.2 Sample Analysis 
For the analysis, the tissues were freeze-dried, homogenized. After that, 30 mg organ for each 
was mixed with 300 μL PBS, followed by extraction and HPLC analysis as the blood samples 
done. The standards of different organs needed to be prepared using the blank tissues collected 
from the rats without any drug administration. A series of commercial DOX was added in the 
different blank organs respectively and then the standards were treated in the same way as the 





Statistical analysis was conducted by using Student’s t-test with p<0.05 as significant difference. 
 
 
5.3 Results and Discussion 
5.3.1 In vivo Pharmacokinetics 
The DOX concentration in the plasma was found after i.v. injection of the commercial DOX, 
TPGS-DOX and TPGS-DOX-FOL in male SD rats at 5mg/kg dose up to 72 hours, which is 
shown in Fig 5-2. We find that the free DOX remains in plasma with shorter circulation time due 
to its short half-life. But, TPGS-DOX conjugates showed a much longer circulation time. This is 
due to the action of TPGS that is said to enhance the circulation time and hence the half-life of 
the pristine drug (Hanauske 2005). TPGS in a parental formulation has been used in clinical trials 
and has been the subject of a pharmacokinetic study (Lissianskaya 2004). In contrast to these, 
TPGS-DOX-FOL conjugate has a shorter circulation time than the TPGS-DOX conjugate and a 
longer circulation time than the free DOX. This might be attributed to the targeting property of 
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folate, resulting in increased cellular uptake and decreased presence of the drug in plasma that 
leads to shorter half-life than the TPGS-DOX conjugate. The amount of drug in the plasma for 
TPGS-DOX-FOL conjugate is greater than the one for pristine DOX and lower for TPGS-DOX 
conjugate. However, all the values fall below the peak concentration (8913.728 ng/mL) with the 
Maximum Tolerated Dose (MTD) administration (8 mg/kg) of pristine DOX (Houba, Boven et al. 
2001). The lowest effective level was also found from the literature to be 5.44 ng/mL (Gavenda, 
Sevcik et al. 2001). 
 
Fig 5-2 Pharmacokinetic profile of the pristine DOX, TPGS-DOX conjugate and TPGS-DOX-





Table 5-1 shows the pharmacokinetic parameters of the pristine DOX and the conjugates, TPGS-
DOX and TPGS-DOX-FOL. It can be seen that the half-life of the drug was 10.5±1.14 h for 
TPGS-DOX-FOL conjugate, 10.2±1.15 h for TPGS-DOX conjugate and 2.69±0.13 h for pristine 
DOX, which is in good agreement with the literature value (Gao, Lee et al. 2005). Here, the folate 
targeted conjugate has almost the same half-life period as the TPGS-DOX conjugate, which has 
3.79 times longer half-life than DOX and is comparable to the previous similar work (Cao and 
Feng 2008). The mean residence time of the drug in plasma was found to be for 9.05±0.69 h 
TPGS-DOX-FOL conjugate, 12.5±1.89 h for TPGS-DOX conjugate and 3.8±0.26 h for DOX. 
Here, the mean residence time of TPGS-DOX is 3.29 times longer than that of the DOX, which is 
almost similar to that of the half-life period. In contrast, the mean residence time of the TPGS-
DOX-FOL conjugate is 2.38 times longer than the pristine DOX and 1.38 times longer than the 
TPGS-DOX conjugate. Actually, increased plasma circulation time gives a positive and increased 
targeting effect (Seymour 1995). Area under the plasma (blood) concentration curve (AUC), 
which is the key therapeutic index, was found to be 6948±634 h.ng/mL for the TPGS-DOX-FOL 
conjugate which is 15 times greater than DOX, 9203±1534 h.ng/mL for the TPGS-DOX 
conjugate which is about 20 times greater than DOX and 480±145 h.ng/mL for the DOX. The 
Total clearance for the conjugate TPGS-DOX-FOL is 0.724±0.06 L/h/kg, for the conjugate 
TPGS-DOX is 0.55±0.09 L/h/kg and for the DOX is 11.2±3.7 L/h/kg. Since the AUC is directly 
proportional to the dose and inversely proportional to the elimination (Mehvar 2004), the total 
clearance for the conjugates TPGS-DOX-FOL, TPGS-DOX and pristine DOX was found to be 
acceptable. The clearance for the folate targeted conjugate is found to be 1.3 times faster than the 
TPGS-DOX and 15 times slower than the DOX. These results show enhanced pharmacokinetic 
properties for TPGS-DOX conjugate and almost not much difference in the folate targeted 
conjugate. The volume of distribution at steady state was found to be 8.24±1.85 L/kg for TPGS-
DOX conjugate and 43.5±13.7 L/kg for DOX, which is 5.3 times greater value. Here, the volume 
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of distribution for the TPGS-DOX-FOL conjugate is 10.9±0.4 L/kg, which is about 4 times 
smaller than the DOX and 1.3 times smaller than TPGS-DOX. Although the conjugate TPGS-
DOX show enhanced pharmacokinetic effects than the other polymer-drug conjugates (Senter, 
Svensson et al. 1995; Veronese, Schiavon et al. 2005), the TPGS-DOX-FOL was found to have 
comparably similar pharmacokinetic properties of TPGS-DOX conjugate than the pristine DOX 
and greater antitumor activity due to the folate targeting. 
 
Table 5-1 Pharmacokinetic parameters of the TPGS-DOX-FOL conjugate, TPGS-DOX conjugate 
and the pristine DOX through i.v. injection at an equivalent dose of 5 mg/kg 
Parameter DOX TPGS-DOX TPGS-DOX-FOL 
T1/2a (h) 2.69±0.13 10.2±1.15 10.5±1.14 
MRTb (h) 3.8±0.26 12.5±1.89 9.05±0.69 
AUC0-αc (h.ng/mL) 480±145 9203±1534 6948±634 
CLtotd (L/h/kg) 11.2±3.7 0.55±0.09 0.724±0.06 
Vdsse (L/kg) 43.5±13.7 8.24±1.85 10.9±0.4 
a half-life time; b mean residence time; c area under the curve; d total clearance; e volume of 
distribution at steady state. 
 
5.3.2 In vivo Biodistribution 
The biodistribution of DOX in tissues, which includes heart, lung, spleen, liver, stomach, 
intestine, kidney and brain, were investigated at time periods of 0.5, 2, 8 and 24 h. The amount of 
DOX distributed in the tissues for DOX, TPGS-DOX and TPGS-DOX-FOL conjugates are 
shown in Fig 5-2 (a), (b) and (c). The peak concentration for DOX accumulation was found at 0.5 
or 2 h. Whereas, the peak concentration for TPGS-DOX and TPGS-DOX-FOL conjugates were 
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similar and is detected at 2 or 8 h. The conjugation of TPGS has significantly affected the 
biodistribution. The results for free DOX and TPGS-DOX conjugate were in agreement with the 








Fig 5-3 The amount of DOX (μg/g) in heart, lung, spleen, liver, stomach, intestine, kidney and 
brain after i.v. administration at 5mg/kg equivalent dose of (a) the free DOX, (b) the TPGS-DOX 
conjugate, (c) the TPGS-DOX-FOL conjugate (mean±SD and n=3) 
 
The highest concentration for DOX was found in heart (49.23±5.27 μg/g organ at 2 h), followed 
by stomach (48.66±8.44 μg/g organ at 2 h), kidney (47.23±9.27 μg/g organ at 0.5 h), lung 
(45.32±9.43 μg/g organ at 2 h), intestine (40.75±4.93 μg/g organ at 2 h), spleen (13.34±0.74 μg/g 
organ at 0.5 h) and liver (13.32±6.13 μg/g organ at 0.5 h). Comparatively, the TPGS-DOX 
conjugate have a peak DOX concentration in heart (10.45±6.03 μg/g organ at 2 h), stomach 
(7.53±5.93 μg/g organ at 0.5 h), kidney (15.66±6.76 μg/g organ at 2 h), lung (22.54±9.43 μg/g 
organ at 8 h), intestine (8.24±4.67 μg/g organ at 2 h), spleen (25.34±8.51 μg/g organ at 0.5 h) and 
liver (15.55±3.25 μg/g organ at 8 h), which is 4.7-, 6.4-, 3-, 2-, 4.9- fold increase respectively. 
The spleen and the liver of the conjugates increased by 1.9- and 1.2- fold than the DOX. For the 
TPGS-DOX-FOL conjugate, the peak concentration in the tissues were found to be 11.52±1.54 




h for kidney, 23.55±5.24 μg/g organ at 8 h for lung, 7.75±3.65 μg/g organ at 8 h for intestine, 
24.64±1.53 μg/g organ at 0.5 h for spleen, 13.63±3.54 μg/g organ at 2 h for liver, which is 4.3-, 
6.8-, 2.3-, 1.9-, 5.3- fold lesser than DOX respectively and the concentration for spleen and liver 
are 1.8-, 1- fold higher than for DOX respectively. Unlike other tissues, brain has a very less 
amount of DOX accumulated and thus for 0.5 h, the amount of DOX for the conjugates TPGS-
DOX and TPGS-DOX-FOL are 1.12±0.02 μg/g organ and 1.04±0.13 μg/g organ. 
 
Table 5-2 AUC values (μg.h/g) of biodistribution in various organs after i.v. injection of free 
DOX or TPGS-DOX (T-D) or TPGS-DOX-FOL (T-D-F) conjugates to SD rats at 5 mg/kg 
equivalent dose 
 HEART LUNG SPLEEN LIVER STOMACH INTESTINE KIDNEY 
DOX 396±233 392±178 231±85 169±129 430±55 246±82 186±53 
T-D 140±49 322±130 751±116 263±86 404±348 103±32 201±77 
T-D-F 129±12 372±108 796±202 222±56 218±121 114±34 283±182 
 
 
Table 5-2 summarizes the AUC values of DOX in various tissues after intravenous injection of 
the free DOX or TPGS-DOX or TPGS-DOX-FOL conjugates. Comparing the TPGS-DOX and 
TPGS-DOX-FOL conjugates with free DOX, the AUC values for liver and spleen of the 
conjugates is higher than DOX, which is 1.5- and 1.3- fold for liver and 3.2- and 3.4- fold for 
spleen respectively. The AUC values are lower for heart and intestine comparing both the 
conjugates with the free DOX i.e. for heart, TPGS-DOX is 2.8- fold and TPGS-DOX-FOL is 3- 
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fold lower than DOX and for intestine, TPGS-DOX is 2.4- fold and TPGS-DOX-FOL is 2.2- fold 
lower than DOX. Also, the AUC values in kidney for conjugates TPGS-DOX and TPGS-DOX-
FOL is 1.08- and 1.5- fold higher than free DOX respectively.  
DOX is a lipophilic molecule and as a consequence it rapidly penetrates into tissues. Therefore, 
normal tissue DOX tissue levels are higher after DOX administration and causes side effects. The 
prodrug is said to deliver decreased amount of drug to the tissues, which proves to lower the side 
effects (Houba, Boven et al. 2001). TPGS, which is has hydrophilic property, when conjugated to 
DOX to produce TPGS-DOX and can prevent diffusion of the prodrug into the tissues. This is 
confirmed by the high peak concentrations of TPGS-DOX and its rapid clearance from normal 
tissues. The folate targeted conjugate, TPGS-DOX-FOL have almost similar distribution as the 
TPGS-DOX conjugate. The amount of drug for TPGS-DOX-FOL conjugate in kidney is little 
higher than the TPGS-DOX, which is due to the overexpression of the folate receptors on the 
apical membrane of the proximal tubules (Lu and Low 2002). The conjugation of DOX to TPGS 
decreased the accumulation of drug in the heart, which is an advantage of the prodrug because 
this organ is the site of cumulative dose-limiting toxicity of DOX. The TPGS-DOX-FOL also has 
similar amount of drug. Thus both the conjugates limit one of the important side effect of DOX, 
namely cardiotoxicity. The gastrointestinal toxicity is also considered as a serious side effects of 
DOX (Mishra and Jain 2000). Since the amount of DOX in stomach and intestine for TPGS-
DOX-FOL and TPGS-DOX conjugates are much lower than for the DOX, this limits the 
gastrointestinal side effects as well. Eventhough, the DOX amount in brain is negligible for DOX, 
it is found in very small amount for TPGS-DOX and TPGS-DOX-FOL conjugates. This confirms 
that the conjugates can cross the blood-brain barrier. Thus, the TPGS-DOX-FOL prodrug 





The in vivo pharmacokinetics results show that TPGS-DOX has higher AUC than the original 
DOX as well as the TPGS-DOX-FOL conjugation. The half-life of both the conjugates, TPGS-
DOX and TPGS-DOX-FOL were found to be similar and higher than for the pristine DOX, due 
to the TPGS conjugation and very minimum effect of folate. As the time increases, the amount of 
drug in the plasma was found to be maximum for the TPGS-DOX conjugate, followed by TPGS-
DOX-FOL and then finally free DOX. The peak values of DOX for the TPGS-DOX conjugate in 
the tissues were reduced, especially in heart, stomach and intestine, which imply decreased side 
effects. In the case of TPGS-DOX-FOL conjugate, the peak value in the heart is almost similar 
and a bit lower in the stomach and intestine, which is confirmed to be advantageous in reducing 













CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
 
6.1 Conclusions 
The main objective of this work is to show the active targeting effects of folate conjugated to a 
prodrug and prove that active targeting is better than the passive targeting. This formulation for 
cancer targeted chemotherapy has been synthesized by conjugating the anticancer drug DOX to 
folic acid and Vitamin E TPGS. They are analyzed using FT-IR and ¹H NMR for confirmation of 
conjugation, in vitro release, cellular uptake, cellular cytotoxicity, in vivo pharmacokinetics and 
biodistribution. There are many works on active targeting of the prodrug or polymer-drug 
conjugates, mainly using folate and herceptin. Also, TPGS acts as a novel amphiphilic polymer to 
overcome many barriers in cancer chemotherapy including uptake, plasma half-life and 
distribution of drug in the tissues. Thus it can be used to improve the therapeutic effects of the 
drug. 
From chapter 3, the TPGS-DOX-FOL conjugate was synthesized via the reaction between the 
TPGS-DOX, which is prepared by the interaction of the succinoylated TPGS and amine group of 
DOX, and FOL-NH-NH2, which is formed by the interaction of NHS ester of folate and 
hydrazine hydrate. The conjugates TPGS-DOX and TPGS-DOX-FOL were characterized by FT-
IR and ¹H-NMR to study the molecular structure and to confirm the conjugation. This shows 
successful synthesis of the conjugates. The drug loading in the case of TPGS-DOX and TPGS-
DOX-FOL was found to be 6 wt% and 13 wt%, which seems comparable to other polymer-DOX 
conjugates. From chapter 4, in vitro release of DOX from the conjugates, TPGS-DOX and TPGS-
DOX-FOL, were found to be pH dependent, where the TPGS-DOX-FOL releases the drug in a 
slow and sustained manner that the TPGS-DOX, whose release is slower than the pristine DOX. 
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TPGS-DOX-FOL conjugates gave higher cellular uptake efficiency that the TPGS-DOX 
conjugate and free DOX at all incubation times, which confirms the targeting effect of folate. The 
in vitro confocal laser scanning microscopy imaging showed that the TPGS-DOX-FOL conjugate 
was found distributed in the cytoplasm of MCF-7 cells, confirming the increased uptake by the 
cell. Also, the CLSM images of TPGS and FOL showed that TPGS can inhibit P-glycoproteins, 
which resulted in its accumulation inside the cell and FOL can enter the cells by targeting. TPGS-
DOX-FOL conjugate showed higher in vitro cytotoxicity in MCF-7 cells and achieved much 
lower IC50 values in comparison with TPGS-DOX and pristine DOX. As the time increases, the 
cytotoxicity also increases for TPGS-DOX-FOL conjugate. However, in vivo studies were 
required to confirm the in vitro results. From chapter 5, the in vivo pharmacokinetics results show 
that TPGS-DOX has higher AUC than the original DOX as well as the TPGS-DOX-FOL 
conjugation. In the case of TPGS-DOX-FOL conjugate, the peak value in the heart is almost 
similar and a bit lower in the stomach and intestine, which is confirmed to be advantageous in 
reducing systemic cytotoxicity, especially preventing cardiotoxicity. 
Among all, this work demonstrated that folate, conjugated to the earlier developed prodrug could 
enhance the cellular uptake and the cytotoxicity of the drug, due to its targeting effect towards the 
folate receptors, which are over expressed on the cancer cells. It is also said to have a slower and 
sustained release due to the increased number of bonds in TPGS-DOX-FOL conjugate than the 
TPGS-DOX conjugate and pristine DOX. The IC50 values for the TPGS-DOX-FOL conjugate 
was found to be much lower than for TPGS-DOX conjugate and free DOX making it a great 
clinical promise for drug delivery. Further, in vivo pharmacokinetics revealed that TPGS-DOX 
conjugate had higher retention time in plasma when compared to TPGS-DOX-FOL, which has a 
retention time higher than the DOX. This is due to the folate targeting that enhances cellular 
uptake and decreases the drug concentration in plasma. In the biodistribution, both the conjugates 
have higher and similar amount of drug in heart, which greatly reduced the side effect of DOX. 
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Also the amount of drug in the stomach and the intestine was found to be in reduced amounts, 
impairing the gastrointestinal side effect of DOX as well. 
 
6.2 Recommendations 
Further, the TPGS-DOX-FOL conjugate can be improved by the following suggestions. 
 To use different tumor models in animals and evaluate the anticancer effect of TPGS-DOX-
FOL conjugate 
 To apply the TPGS-DOX-FOL conjugate in clinical phase I test for further investigation in 
therapeutic effects for the treatment of cancer 
 To develop folate targeted polymer-drug conjugate using TPGS with other hydrophobic drugs 
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